ID	GeneID	SeqNo	Drug	GeneName	ApprovalLevel	AddedByUser	PrimaryReference	ReviewReferece	SecondaryReference	NucleotidePosition	Type	Ref	Alt	EstimatedCodonPosition	ReportedCodonPosition	AminoAcid	Note	TimePeriod	StudyPopulation	Country	MolecularDetectionMethod	GeneCoverage	ResistancePattern	MIC	SusceptibilityTestingMethod	RTotalIsolates	RSIsolatesWMutation	AdditionalMutations	HighQuality	PMID	OverallSequentialNumber	NoHC
1	3795	76	EMB	embB			Srivastava S JMM 2009			1110	SNP	G	T	370	370	Leu/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V377M, E378A, F398H, N399H, E405P, G406A	0	19010731	955	0
2	3795	77	EMB	embB			Srivastava S JMM 2009			1113	SNP	CG	GT	371	371	Pro/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB D299E, A356S, E378K; embR R230W, L292M, L303E	0	19010731	956	0
3	3795	78	EMB	embB			Srivastava S JMM 2009			1122	SNP	GC	TG	374	374	Gly/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	embC W395C, N400P; embC G288W, V303G; embR A187V, R230W, I369T	0	19010731	957	0
6	3795	81	EMB	embB			Srivastava S JMM 2009			1131	SNP	G	C	377	377	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, E378A, Y384N, N400K, V452L	0	19010731	960	0
8	3795	83	EMB	embB			Srivastava S CurrMicro 2006			1134	SNP	A	G	378	378	Glu/Ala		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method	23/23	2/0	Both of these isolates were mutated at embB Asp299Glu. One was also mutated at embB Pro446His and Ile465Asp, as well as embC Thr270Ile and 254 Synonymous (GCC/GCG). The other isolate was mutated at embBArg469Pro and Arg 471Pro. R/Tot and R/S calculated fr	0	16972132	962	0
9	3795	84	EMB	embB			Srivastava S JMM 2009			1136	SNP	GCG	ACC	379	379	Ala/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S; embC V287F, Y309N; embR L320V S326N, V350G, H351Q, R356G, I369T	0	19010731	963	0
10	3795	85	EMB	embB			Srivastava S JMM 2009			1137	SNP	G	T	379	379	Ala/Asp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embB A356F, A357V, L359I, E378A, Y384N, A388G, N399D, G406P; embC A247P, T270I, I297T	0	19010731	964	0
11	3795	86	EMB	embB			Srivastava S CurrMicro 2006			1139	SNP	AGC	CGT	380	380	Ser/Arg		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Pro397Gln on embB. R/Tot and R/S calculated from Table 1.	0	16972132	965	0
12	3795	87	EMB	embB			Srivastava S JMM 2009			1140	SNP	G	A	380	380	Ser/Asp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, P397T, G406D, G448V; embC I287L, W326R	0	19010731	966	0
13	3795	88	EMB	embB			Srivastava S JMM 2009			1152	SNP	A	A	384	384	Tyr/Asn		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, V377G, E378A,  N400K, V452L	0	19010731	967	0
14	3795	89	EMB	embB			Srivastava S JMM 2009			1164	SNP	G	C	388	388	Ala/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embB A356F, A357V, L359I, E378A, A379D, Y384N, N399D, G406P; embC A247P, T270I, I297T	0	19010731	968	0
15	3795	90	EMB	embB			Srivastava S JMM 2009			1184	SNP	TGG	CGT	395	395	Trp/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, S366P, A434G, V435G, V436G, T437A; embC T270I	0	19010731	969	0
16	3795	91	EMB	embB			Srivastava S JMM 2009			1185	SNP	G	C	395	395	Trp/Cys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	embC G374V, N400P; embC G288W, V303G; embR A187V, R230W, I369T	0	19010731	970	0
17	3795	92	EMB	embB			Srivastava S JMM 2009			1190	SNP	CCG	ACC	397	397	Pro/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, S380D, G406D, G448V; embC I287L, W326R	0	19010731	971	0
18	3795	93	EMB	embB			Srivastava S CurrMicro 2006			1191	SNP	C	A	397	397	Pro/Gln		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.	0	16972132	972	0
20	3795	95	EMB	embB			Srivastava S JMM 2009			1194	SNP	T	A	398	398	Phe/Tyr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, A310R, D311R, V369A, P375A, P461S; embC T270I; embR G240R	0	19010731	974	0
23	3795	98	EMB	embB			Srivastava S JMM 2009			1199	SNP	AAC	CCG	400	400	Asn/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	embC G374V, W395C; embC G288W, V303G; embR A187V, R230W, I369T	0	19010731	977	0
24	3795	99	EMB	embB			Srivastava S JMM 2009			1201	SNP	C	A	400	400	Asn/Lys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, E378A, Y384N, V452L	0	19010731	978	0
25	3795	100	EMB	embB			Srivastava S JMM 2009			1203	SNP	G	A	401	401	Gly/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	ER	16ug/ml	Proportion method, E-Test	44/44	1/0	embB G331R, G374V, G374V; embC I297T; embR D223E	0	19010731	979	0
26	3795	101	EMB	embB			Srivastava S JMM 2009			1214	SNP	GAA	CCG	405	405	Glu/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB L370R, V377M, E378A, F398H, N399H, G406A	0	19010731	980	0
27	3795	102	EMB	embB			Srivastava S JMM 2009			1217	SNP	GGC	CCG	406	406	Gly/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embB A356F, A357V, L359I, E378A, A379D, Y384N, A388G, N399D; embC A247P, T270I, I297T	0	19010731	981	0
30	3795	105	EMB	embB			Srivastava S JMM 2009			1218	SNP	GC	AT	406	406	Gly/Asp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, S380D, P397T, G448V; embC I287L, W326R	0	19010731	984	0
31	3795	106	EMB	embB			Ramaswamy SV AAC 2000			1218	SNP	G	A	406	406	Gly/Asp		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Asp4Asn in embA	1	10639358	985	13
32	3795	107	EMB	embB			Ramaswamy SV AAC 2000			1218	SNP	G	C	406	406	Gly/Ala		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	75/108	2/0	In one of the isolates, -11 C/A in embA and Met306Ile in embB.	0	10639358	986	0
33	3795	108	EMB	embB			Srivastava S CurrMicro 2006			1218	SNP	GC	CG	406	406	Gly/Ala		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.	0	16972132	987	0
34	3795	109	EMB	embB			Lee AS AAC 2004			1269	SNP	G	A	423	423	Met/Ile		Published 2004	EMB-R (n=25) and EMB-S (n=20) isolates. Total N=45.	Singapore	Sequencing	Whole gene	EI	N.S.	BACTEC 460	25/45	1/0	None in region amplified (see Gene coverage).	0	15504879	988	13
35	3795	110	EMB	embB			Srivastava S JMM 2009			1290	SNP	C	T	430	430	Pro/Leu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB G406D, A431T; embC I297T	0	19010731	989	0
36	3795	111	EMB	embB			Srivastava S JMM 2009			1292	SNP	GCG	ACC	431	431	Ala/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB G406D,P430L; embC I297T	0	19010731	990	0
37	3795	112	EMB	embB			Srivastava S JMM 2009			1302	SNP	G	C	434	434	Arg/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, S366P, W395R, V435G, V436G, T437A; embC T270I	0	19010731	991	0
38	3795	113	EMB	embB			Srivastava S JMM 2009			1305	SNP	G	C	435	435	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, S366P, W395R, A434G, V436G, T437A; embC T270I	0	19010731	992	0
39	3795	114	EMB	embB			Srivastava S JMM 2009			1308	SNP	G	C	436	436	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, S366P, W395R, A434G, V435G, T437A; embC T270I	0	19010731	993	0
40	3795	115	EMB	embB			Srivastava S JMM 2009			1310	SNP	ACC	GCG	437	437	Thr/Ala		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, S366P, W395R, A434G, V435G, V436G; embC T270I	0	19010731	994	0
41	3795	116	EMB	embB			Srivastava S CurrMicro 2006			1338	SNP	CG	AT	446	446	Pro/His		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	Asp299Glu, Glu378Ala, and Ile465Asp in embB; Thr270Ile and 254 Synonymous (GCC/GCG) in embC. R/T and R/S calculated from Table 1.	0	16972132	995	0
42	3795	117	EMB	embB			Srivastava S JMM 2009			1344	SNP	GC	TG	448	448	Gly/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, S380D, P397T, G406D; embC I287L, W326R	0	19010731	996	0
44	3795	119	EMB	embB			Srivastava S JMM 2009			1377	SNP	GC	CG	459	459	Gly/Ala		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, N318K, N368A, S380R, P397Q,  R460C; embR T32P, D53H	0	19010731	998	0
45	3795	120	EMB	embB			Srivastava S JMM 2009			1379	SNP	CGT	TGC	460	460	Arg/Cys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB E368A, S380R, P397Q; embC A244T, G288W, V303G embR L172R	0	19010731	999	0
46	3795	121	EMB	embB			Srivastava S JMM 2009			1380	SNP	T	G	460	460	Arg/Leu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB S347I, E368D; embC I297T; embR R230W, I396T	0	19010731	1000	0
47	3795	122	EMB	embB			Srivastava S JMM 2009			1382	SNP	CCG	AGC	461	461	Pro/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, A310R, D311R, V369A, P375A, F398Y; embC T270I; embR G240R	0	19010731	1001	0
49	3795	124	EMB	embB			Srivastava S CurrMicro 2006			1407	SNP	T	G	469	469	Arg/Pro		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	Asp299Glu, Glu378Ala, and Arg471Pro in embB. R/T and R/S calculated from Table 1.	0	16972132	1003	0
50	3795	125	EMB	embB			Srivastava S CurrMicro 2006			1413	SNP	T	G	471	471	Arg/Pro		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	Asp299Glu, Glu378Ala, and Arg469Pro in embB. R/T and R/S calculated from Table 1.	0	16972132	1004	0
51	3795	126	EMB	embB			Ramaswamy SV AAC 2000			1491	SNP	A	G	497	497	Gln/Arg		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	30-50ug/ml	BACTEC 460, agar diffusion method	75/108	3/0	In one of the isolates: -12 C/T in embA, Ser501Trp in iniA.	1	10639358	1005	13
53	3795	128	EMB	embB			Sreevatsan S AAC 1997			1890	SNP	C	T	630	630	Thr/Ile	Found in two epidemiologically related resistant strains.	Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	>40ug/ml	BACTEC 460, agar diffusion method	69/99	2/0		0	9257740	1007	0
55	3795	130	EMB	embB			Ramaswamy SV AAC 2000			2235	SNP	G	A	745	745	Gly/Asp		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Gly308Arg in iniA	0	10639358	1009	13
56	3795	131	EMB	embB			Ramaswamy SV AAC 2000			2877	SNP	A	C	959	959	Asp/Ala		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0		0	10639358	1010	0
57	3795	132	EMB	embB			Ramaswamy SV AAC 2000			3000	SNP	T	G	1000	1000	Met/Arg		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0		0	10639358	1011	0
59	1267c	1	EMB	embR			Ramaswamy SV AAC 2000			-273	ins		A	-273	-273	intergenic	Hypothesis cited in paper: if embR is a transcription regulator for embAB, then an over-active mutant form will produce enough arabinosyltransferase to compensate for given level of ethambutol, resulting in de facto resistance. Needs more evidence.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	20-40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0		0	10639358	1013	0
60	1267c	2	EMB	embR			Srivastava S JMM 2009			21	SNP	G	C	7	7	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	48ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M; embC A247P, I297L, W326R	0	19010731	1014	0
61	1267c	3	EMB	embR			Srivastava S JMM 2009			96	SNP	C	C	32	32	Thr/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, N318K, E368A, S380R, P397Q, G459A, R460C; embR D53H	0	19010731	1015	0
63	1267c	5	EMB	embR			Srivastava S JMM 2009			330	SNP	C	T	110	110	Cys/Tyr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embC G288W, V303G	0	19010731	1017	0
64	1267c	6	EMB	embR			Srivastava S JMM 2009			516	SNP	G	T	172	172	Leu/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB E368A, S380R, P397Q, R460C; embC A244T, G288W, V303G	0	19010731	1018	0
65	1267c	7	EMB	embR			Srivastava S JMM 2009			528	SNP	C	T	176	176	Ala/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M, A431T; embC G272S, H285Y, M300R, A307T; embR I369T	0	19010731	1019	0
66	1267c	8	EMB	embR			Srivastava S JMM 2009			558	SNP	G	G	186	186	Arg/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	24ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, E368A, S380R, P397Q, R460C; embC I297T; embR S188R, E200A, L211M	0	19010731	1020	0
67	1267c	9	EMB	embR			Srivastava S JMM 2009			561	SNP	C	T	187	187	Ala/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB G374V, W395C, N400P; embC G288W, V303G; embR R230W, I369T	0	19010731	1021	0
68	1267c	10	EMB	embR			Srivastava S JMM 2009			563	SNP	AGC	CGT	188	188	Ser/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB D299E, E378A, R469P, R471P; embR L211M, L320V	0	19010731	1022	0
69	1267c	11	EMB	embR			Srivastava S JMM 2009			600	SNP	A	G	200	200	Glu/Ala		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	24ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, E368A, S380R, P397Q, R460C; embC I297T; embR S186G, S188R, L211M	0	19010731	1023	0
71	1267c	13	EMB	embR			Srivastava S JMM 2009			669	SNP	T	A	223	223	Asp/Glu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	embB G331R, V360M, G374V, G401S; embC I297T	0	19010731	1025	0
72	1267c	14	EMB	embR			Srivastava S JMM 2009			689	SNP	CGT	TGG	230	230	Arg/Trp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB S347I, E368D, R460L; embC I297T; embR I396T	0	19010731	1026	0
73	1267c	15	EMB	embR			Srivastava S JMM 2009			719	SNP	GGC	CGT	240	240	Gly/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, A319R, D311R, V369A, P375A, F398Y, P461S;  embC T270I	0	19010731	1027	0
75	1267c	17	EMB	embR			Srivastava S JMM 2009			908	SNP	CTG	GAA	303	303	Leu/Glu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB D299E, A356S, P371R, E378K;  embR R230W, L292M	0	19010731	1029	0
77	1267c	19	EMB	embR			Srivastava S JMM 2009			978	SNP	G	A	326	326	Ser/Asn		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F, Y309N; embR L320V, V350G, H351Q, R356G, I369T	0	19010731	1031	0
78	1267c	20	EMB	embR			Srivastava S JMM 2009			1050	SNP	G	C	350	350	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, H351Q, R356G, I369T	0	19010731	1032	0
79	1267c	21	EMB	embR			Srivastava S JMM 2009			1053	SNP	T	G	351	351	His/Glu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, R356G, I369T	0	19010731	1033	0
80	1267c	22	EMB	embR			Srivastava S JMM 2009			1068	SNP	G	G	356	356	Arg/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, H351Q, I369T	0	19010731	1034	0
81	1267c	23	EMB	embR			Srivastava S JMM 2009			1107	SNP	T	C	369	369	Ile/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, H351Q, R356G	0	19010731	1035	0
82	1267c	24	EMB	embR			Ramaswamy SV AAC 2000			1137	SNP	A	G	379	379	Gln/Arg	(If proposed mechanism is correct, would we expect to see synergistic action between resistance-conferring mutations in embR and in embAB? Look for evidence.)	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	20-40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0		0	10639358	1036	0
83	1267c	25	EMB	embR			Srivastava S JMM 2009			1188	SNP	T	C	396	396	Ile/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB S347I, E368D, R460L; embC I297T; embR R230W	0	19010731	1037	0
84	3124	1	EMB	Rv3124			Ramaswamy SV AAC 2000			-49	SNP	A	G	-16	-16	intergenic	Role of change unclear, due to additional mutations.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Met306Ile in embB.	0	10639358	1038	0
87	0340	1	EMB	Rv0340			Ramaswamy SV AAC 2000			-24	del		G	-24	-24	Frameshift		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	75/108	1/0	Asn396Asp in embC, Gly350Asp and Pro913Ser in embA, and Leu276Arg in Rv3124.	0	10639358	1041	0
89	0341	1	EMB	iniB			Ramaswamy SV AAC 2000			-268	SNP	C	T	-89	-89			Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Gln497Lys in embB.	0	10639358	1043	0
96	3266c	1	EMB	rmlD			Ramaswamy SV AAC 2000			-214	SNP	G	T	-71	-71			Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	2/0		0	10639358	1050	0
99	1484	2	ETH	inhA			Ristow M Lancet 1995			304	SNP	AT	CC	95	95	Ile/Pro	The authors designed this study as a rapid PCR-based restriction-analysis screen, with the purpose of looking for the inhA94 mutation described in previous papers; however, they did not detect this mutation. All 5 sensitive and 35 of the resistant isolate	Published 1995	Clinical M.tb isolates, including pan-susceptible (n=5), INH-R only (n=10), ETH-R only (n=4), INH-R and ETH-R (n=6), and resistant to INH and two or more other drugs (n=22). Total N=47	Germany, Nepal	Sequencing	region around inhA 94	MDR	N.S.	Proportion method.	32/47	7/0	None found in the fragment analyzed.	0	7637495	1053	0
101	3854c	2	ETH	ethA, aka, etaA			Morlock GP AAC 2003			110	del		A	37		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr	0	14638486	1055	0
104	3854c	5	ETH	ethA, aka, etaA			DeBarber AE PNAS 2000			153	SNP	C	T	51	51	Pro/Leu	This mutation was found in 1 (7%) of 15 isolates.	Published 2000	Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.	South Africa	Sequencing	Whole gene	EthL	N.S.	Proportion method.	40132	1/0	None found in region analyzed.	0	10944230	1058	0
105	3854c	6	ETH	ethA, aka, etaA			Morlock GP AAC 2003			165	SNP	A	C	55	55	Asp/Ala	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Gly279Asp, mabA -15 C/T	0	14638486	1059	0
106	3854c	7	ETH	ethA, aka, etaA			DeBarber AE PNAS 2000			174	SNP	A	C	58	58	Asp/Ala	This mutation was found in 1 (7%) of 15 isolates.	Published 2000	Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	40132	1/0	None found in region analyzed.	0	10944230	1060	0
108	3854c	9	ETH	ethA, aka, etaA			Morlock GP AAC 2003			338	ins		A	113		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	100ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr	0	14638486	1062	0
109	3854c	10	ETH	ethA, aka, etaA			DeBarber AE PNAS 2000			558	SNP	C	A	186	186	Thr/Lys	This was the only mutation found in the laboratory-generated ETH-R strain.	Published 2000	Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	40132	1/0	None found in region analyzed.	0	10944230	1063	0
111	3854c	12	ETH	ethA, aka, etaA			Morlock GP AAC 2003			701	del		T	234		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr	0	14638486	1065	0
113	3854c	14	ETH	ethA, aka, etaA			Morlock GP AAC 2003			767	del		G	256		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr	0	14638486	1067	0
114	3854c	15	ETH	ethA, aka, etaA			DeBarber AE PNAS 2000			809	ins		N	270		Frameshift	This mutation was found in 1 (7%) of 15 isolates.	Published 2000	Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.	South Africa	Sequencing	Whole gene	HEth	N.S.	Proportion method.	40132	1/0	None found in region analyzed.	0	10944230	1068	0
115	3854c	16	ETH	ethA, aka, etaA			DeBarber AE PNAS 2000			1026	SNP	C	A	342	342	Thr/Lys	This mutation was found in 3 (20%) of 15 isolates.	Published 2000	Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.	South Africa	Sequencing	Whole gene	HEth	N.S.	Proportion method.	40132	3/0	None found in region analyzed.	0	10944230	1069	0
116	3854c	17	ETH	ethA, aka, etaA			Morlock GP AAC 2003			1014	SNP	T	G	338	338	Ile/Ser	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr, mabA -15 C/T	0	14638486	1070	0
118	3854c	19	ETH	ethA, aka, etaA			Morlock GP AAC 2003			1155	SNP	G	A	385	385	Gly/Asp	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr, mabA -15 C/T	0	14638486	1072	0
120	3854c	21	ETH	ethA, aka, etaA			Morlock GP AAC 2003			1239	SNP	G	A	413	413	Gly/Asp	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	None found in region analyzed.	0	14638486	1074	0
121	3854c	22	ETH	ethA, aka, etaA			Morlock GP AAC 2003			1289	del		C	430		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr	0	14638486	1075	0
122	3854c	23	ETH	ethA, aka, etaA			Morlock GP AAC 2003			1322	del		GC	441		Frameshift	An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	None found in region analyzed.	0	14638486	1076	0
124	1483	1	ETH	mabA, fabG1			Lee H Int J Tuberc Lung Dis 2000			-46	SNP	C	T	-15	-15		This C/T mutation was found in all 12 (100%) of the INH-R and ETH-R isolates, and in 2 (17%) of the 12 INH-R isolates. This region is believed to be the regulatory region for the inhA gene.	Published 2000	Clinical M.tb isolates; 12 INH-R only and 12 INH-R + ETH-R; none were involved in a single major outbreak of the disease (and so less likely to be related). N=24	South Korea	Sequencing	Whole	HEth, HREth	40-80ug/ml	Proportion method.	40171	40149	No mutation in inhA94 found.	0	10815738	1078	0
125	1483	2	ETH	mabA, fabG1			Morlock GP AAC 2003			-52	SNP	G	T	-17	-17		This is the only mutation found in this region other than the -15 C/T substitution.	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole	EthH	100ug/ml	Microplate almar blue assay	41/41	1/0	inhA Ile21Thr	0	14638486	1079	0
128	0006	3	FLQ	gyrA			Matrat S AAC 2006 Dec			264	SNP	G	C	88	88	Gly/Ala		Published 2006		N.S.	Sequencing	nt 247-282 of gyrA	Resistant to: sparfloxacin, gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ofloxacin, enoxacin, temafloxacin, flumequine, oxolinic acid, nalidixic acid, pipemidic acid; and to coumarin.	2x to 16x higher than WT (H37Rv) MICs for the same drugs.	Proportion method	39938	5/0	N.S.	0	17015626	1082	0
130	0006	5	FLQ	gyrA			Takiff HE AAC 1994			270	SNP	C	T	90	90	Ala/Val		Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4-8	BACTEC 460	3/54	3/0	gyrA: Ser95Thr	1	8031045	1084	13
131	0006	6	FLQ	gyrA			Aubry A AAC 2006			270	SNP	C	G	90	90	Ala/Gly		Published 2006		France	Sequencing	QRDRs on gyrA and gyrB	Hypersusceptible to all 5 drugs, with MICs significantly lowered compared to H37Rv.	GAT 0.12-0.5, MOX 0.12-0.25, LVX 0.25-1, OFX 0.25-1, and ENX 2-8 ug/ml.	Proportion method	14/15	0/4	gyrA: Thr80Ala	0	16377674	1085	0
135	0006	10	FLQ	gyrA			Bravao LTC JCM 2009			282	SNP	A	T	94	94	Asp/Phe		Published 2009		Phillipines	Sequencing	225-bp gyrA QRDR	HROfx	N.S.	Proportion method	9/102	1/0	gyrA: Ser95Thr	0	19846642	1089	0
137	0006	12	FLQ	gyrA			Takiff HE AAC 1994			282	SNP	A	G	94	94	Asp/Gly		Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 8	BACTEC 460	5/54	5/0	gyrA: Ser95Thr	1	8031045	1091	13
138	0006	13	FLQ	gyrA			Takiff HE AAC 1994			282	SNP	A	C	94	94	Asp/Ala		Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4	BACTEC 460	1/54	1/0	gyrA: Ser95Thr	1	8031045	1092	13
139	0006	14	FLQ	gyrA			Sulochana S J Chemother 2007			282	SNP	A	T	94	94	Asp/Val		Published 2007		India	Sequencing	320-bp gyrA QRDR, 360-bp gyrB QRDR	Moderately resistant to OFX.	OFX: 16-64	Absolute concentration method	71/118	7/0	gyrA: Ser95Thr	0	17434825	1093	0
140	0006	15	FLQ	gyrA			Kapur V Arch PathLabMEd 1995			285	SNP	G	C	95	95	Ser/Thr													0	7848059	1094	0
141	0006	16	FLQ	gyrA			Kam KM Microb Drug Res 2006			306	SNP	C	A	102	102	Pro/His													1	16584301	1095	13
144	0005	2	FLQ	gyrB			Duong DA AAC 2009			1374	SNP	C	T	458	458	Ser/Phe	Mutation reported as S486F	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB	0	19721073	1098	0
149	0005	7	FLQ	gyrB			Duong DA AAC 2009			1416	SNP	A	C	472	472	Asp/Ala	Mutation reported as D500A	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA A90V	0	19721073	1103	0
150	0005	8	FLQ	gyrB			Duong DA AAC 2009			1443	SNP	G	C	481	481	Gly/Ala	Mutation reported as G509A	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB	0	19721073	1104	0
151	0005	9	FLQ	gyrB			Lee AS Int J Infect Dis 2002			1515	SNP	A	C	505	505	Asp/Ala													0	12044302	1105	0
153	0005	11	FLQ	gyrB			Duong DA AAC 2009			1530	SNP	A	C	510	510	Asn/Thr	Mutation reported as N538T	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA A90V	0	19721073	1107	0
154	0005	12	FLQ	gyrB			Mokrousov I AAC 2008			1531	SNP	C	A	510	510	Gln/Lys		2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	0	18559646	1108	0
156	0005	14	FLQ	gyrB			Duong DA AAC 2009			1536	SNP	A	T	512	512	Glu/Val	Mutation reported as E540V	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB	0	19721073	1110	0
159	0005	17	FLQ	gyrB			Mokrousov I AAC 2008			1545	SNP	C	T	515	515	Ala/Val		2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	0	18559646	1113	0
160	0005	18	FLQ	gyrB			Mokrousov I AAC 2008			1647	SNP	A	T	549	549	Gln/His		2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	0	18559646	1114	0
162	1694	2	AMI	tlyA			Maus CE AAC 2005			26	del		C	9		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1116	0
166	1694	6	AMI	tlyA			Maus CE AAC 2005			23	del		A	8		Frameshift	Mutation found in the clinical group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	RESKCapVio Ami	Cap 80ug/ml	Proportion method	18/18	1/0	None found in region analyzed.	0	15673735	1120	0
167	1694	7	AMI	tlyA			Maus CE AAC 2005 Feb			68	del		GCC	23	23	del A		Published 2005	Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18	USA	Sequencing	Whole gene	HRESKCapVioAmi	K 20ug/ml	Proportion method	16/18	1/0	None found in region analyzed.	0	15673735	1121	0
168	1694	8	AMI	tlyA			Maus CE AAC 2005			201	SNP	C	A	67	67	Ala/Glu	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1122	0
170	1694	10	AMI	tlyA			Maus CE AAC 2005			218	ins		C	73		Frameshift	Mutation found in the clinical group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	HRESKCapVioAmi	Cap 80ug/ml	Proportion method	18/18	1/0	None found in region analyzed.	0	15673735	1124	0
171	1694	11	AMI	tlyA			Maus CE AAC 2005			273	SNP	C	A	91	91	Ala/Glu	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	Cap 40ug.ml, Vio <10ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1125	0
172	1694	12	AMI	tlyA			Maus CE AAC 2005			308	del		G	103		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1126	0
173	1694	13	AMI	tlyA			Maus CE AAC 2005			354	SNP	T	C	118	118	Leu/Pro	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 40ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1127	0
174	1694	14	AMI	tlyA			Maus CE AAC 2005			384	SNP	T	A	128	128	Val/Glu	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1128	0
175	1694	15	AMI	tlyA			Maus CE AAC 2005			395	ins		C	132		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1129	0
176	1694	16	AMI	tlyA			Maus CE AAC 2005			398	del		A	133		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1130	0
177	1694	17	AMI	tlyA			Maus CE AAC 2005 Feb			450	SNP	T	C	150	150	Leu/Pro		Published 2005	Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18	USA	Sequencing	Whole gene	HRSCap	K <5ug/ml Cap 40ug/ml	Proportion method	16/18	0/1	None found in region analyzed.	0	15673735	1131	0
178	1694	18	AMI	tlyA			Maus CE AAC 2005			476	del		G	159		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	Cap 40ug/ml, Vio <10ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1132	0
179	1694	19	AMI	tlyA			Maus CE AAC 2005			548	SNP	C	T	183	183	Pro/Leu	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1133	0
180	1694	20	AMI	tlyA			Maus CE AAC 2005			551	SNP	C	T	184	184	Gln/STOP	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	Cap 40ug/ml, Vio <10ug/ml	Proportion method	30/30	5/0	None identified specifically.	0	15673735	1134	0
181	1694	21	AMI	tlyA			Maus CE AAC 2005			554	SNP	T	G	185	185	Phe/Leu	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1135	0
182	1694	22	AMI	tlyA			Maus CE AAC 2005			584	del		G	195		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1136	0
183	1694	23	AMI	tlyA			Maus CE AAC 2005			653	del		T	218		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1137	0
184	1694	24	AMI	tlyA			Maus CE AAC 2005 Feb			653	ins		C	218	218	Frameshift		Published 2005	Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18	USA	Sequencing	Whole gene	HRESKCapVioAmI	K 20ug/ml	Proportion method	16/18	1/0	None found in region analyzed.	0	15673735	1138	0
185	1694	25	AMI	tlyA			Maus CE AAC 2005			671	del		GT	224		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1139	0
186	1694	26	AMI	tlyA			Maus CE AAC 2005 Feb			709	SNP	T	G	236	236	Asn/Lys		Published 2005	Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18	USA	Sequencing	Whole gene	HSCapVio	K <5ug/ml Cap 80ug/ml	Proportion method	16/18	0/1	None found in region analyzed.	0	15673735	1140	0
187	1694	27	AMI	tlyA			Maus CE AAC 2005			713	SNP	G	A	238	238	Glu/Lys	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1141	0
188	1694	28	AMI	tlyA			Maus CE AAC 2005			758	del		C	253		Frameshift	Mutation found in the lab-produced group.	Published 2005	Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.	0	15673735	1142	0
222	1908c	103	INH	katG			Baker LV AAC 2005			702	SNP	G	A	234	234	Gly/Glu		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0		0	15793126	238	0
224	1908c	105	INH	katG			Chan RCY JAC 2007			708	SNP	A	C	236	236	Asn/Thr		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	240	0
225	1908c	106	INH	katG			Hai Hua Lin TubercRespirDis 2007			715	SNP	C	G	238	238	Asn/Lys		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	katG S140R	0	2007582629	241	0
226	1908c	107	INH	katG			Baker LV AAC 2005			724	SNP	C	G	241	241	Pro/Pro		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	2/0		0	15793126	242	0
229	1908c	110	INH	katG			Gagneux S PLOS Path 2006			753	SNP	C	T	251	251	Thr/Met													0	16789833	245	0
231	1908c	112	INH	katG			Sekigushi J JCM 2007			771	SNP	T	C	257	257	Met/Thr		2007	Japan & Polan	Japan, Poland	Multiplex  Sequencing	Whole gene			Middlebrook 7H10 agar medium method Ogawa egg based medium method, Rapid broth method(BACTEC)	38/138	1/0	R463L V780P katG, -15C/T upstream of mabA	0	17596354	247	0
232	1908c	113	INH	katG			Lavender C AAC 2005			771	SNP	G	T	257	257	Met/Ile		2001-2003	Victorian Inf DiseaseReference Lab	Australia	Multiplex allele specific PCR Assay	Whole gene	HR	0.1ug/ml I, 1ug/ml R	BACTEC MGIT960	52/104	1/0		0	16189082	248	0
233	1908c	114	INH	katG			Cockerill FR JID 1995			774	SNP	A	G	258	258	Asn/Ser		1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	0.25ug/ml	Proportion method		0/1	Pro2Ser, Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Ala264Thr, Tyr337Phe	0	7798673	249	0
234	1908c	115	INH	katG			Rouse DA AAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	786	SNP	C	G	262	262	Thr/Arg	site directed mutagenesis	1995	washington DC, Bethesda, South Korea,	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	1 ug/ml	Absolute concentration method	26/26	1/0		0	8585728	250	0
236	1908c	117	INH	katG			Chan RCY JAC 2007			803	del		G	268	268	Frameshift		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	252	0
240	1908c	121	INH	katG			Morlock GP AAC 2003			837	SNP	G	A	279	279	Gly/Asp		2003	United States, Russia, Brazil	Brazil	Sequencing	fragment encompassing codons 249 to 342	HEth	>32 I, >200 Eth	Microplate alamar blue assay	17/41	1/0	D55/A ethA,L44L inhA ORF, C(-15)T inhA regulator	1	14638486	256	10
242	1908c	123	INH	katG			Cockerill FR JID 1995			843	SNP	C	T	281	281	Ala/Val		1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	1ug/ml	Proportion method		1/0	Pro2Ser, Ser17Asn, Met126Ile, Gly169Ala, Gln224Glu, Ala264Val, Try337Cys, Arg463Leu	0	7798673	258	0
243	1908c	124	INH	katG			Abe C JCM 2008			855	SNP	G	A	285	285	Gly/Asp		Published in 2008		Japan	Sequencing	Whole gene	H		MGIT 960	96/96	1/0		0	18508939	259	10
244	1908c	125	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		866	ins		N	289	289	Frameshift?	Primary paper not found.												0	10645439	260	0
245	1908c	126	INH	katG			Chan RCY JAC 2007			867	SNP	G	C	289	289	Glu/Asp		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	261	0
247	1908c	128	INH	katG			Sekigushi J JCM 2007			885	SNP	A	C	295	295	Gln/Pro		2007	Japan & Poland	Poland	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0		0	17596354	263	0
248	1908c	129	INH	katG			Sekigushi J JCM 2007			891	SNP	G	T	297	297	Gly/Val		2007	Japan & Poland	Poland	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0		0	17596354	264	0
250	1908c	131	INH	katG			Huang WL JCM 2009			897	SNP	G	C	299	299	Gly/Ala		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	266	0
253	1908c	134	INH	katG			Gagneux S PLOS Path 2006			902	ins		T	301	301	Frameshift													0	16789833	269	0
254	1908c	135	INH	katG			Cockerill FR JID 1995	Hazbon MH AAC 2006		906	SNP	C	G	302	302	Ser/Arg		1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	8ug/ml	Proportion method	40071	1/0	Ser315Thr and Arg463Leu in katG.	0	7798673	270	0
255	1908c	136	INH	katG			Bolotin S JAC 2009			912	SNP	A	C	304	304	Tyr/Ser		1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0		0	19520719	271	0
256	1908c	137	INH	katG			Bostanabad SZ Tuberk Torak 2007			915	SNP	G	C	305	305	Gly/Ala		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	3/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	272	0
258	1908c	139	INH	katG			Bostanabad SZ Tuberk Torak 2007			921	SNP	G	C	307	307	Gly/Ala		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	274	0
259	1908c	140	INH	katG			Ramaswamy SV J Med Micro 2004			921	SNP	G	A	307	307	Gly/Glu		1996-1998	Jose Gonzalez hospital Mexico	Mexico	Directed Oligonucleotide array, Sequencing	codon 228-357	HRSE	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	Ser450Leu rpoB,	0	14729930	275	0
261	1908c	142	INH	katG			Bostanabad SZ Tuberk Torak 2007			927	SNP	G	T	309	309	Gly/Cys	GTT gives Val, see also ref Zakerbostanabad S IngGenEvol 2008	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	277	0
262	1908c	143	INH	katG			Bostanabad SZ Tuberk Torak 2007			927	SNP	G	C	309	309	Gly/Ser		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	278	0
263	1908c	144	INH	katG			Kim SY Diagn Micro Inf Dis 2003			927	SNP	G	A	309	309	Gly/Asp		200-2002	Korean Institute of TB, Neodin Medical instittue, Kangman st Mary hosptial in South Korea	South Korea	PCR-SSCP, Sequencing	210 bp fragment spanning codon 315	HR	0.2 ug/ml I 40 ug/ml R	Proportion method	71/97	2/0	inhA Ribosomal binding site C/T	0	14596968	279	0
264	1908c	145	INH	katG			Bostanabad SZ Tuberk Torak 2007			927	SNP	GT	TC	309	309	Gly/Phe		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	280	0
265	1908c	146	INH	katG			Huang WL JCM 2009			929	del		A	310	310	Frameshift		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	281	0
268	1908c	149	INH	katG			Chan RCY JAC 2007			933	SNP	A	G	311	311	Asp/Gly		2007	Grantham Hosptial and Public Health Lab, Hongkong	Hong Kong	PCR-SSCP, Sequencing	703 bp fragment	HEP	1ug/ml I, 4ug/ml E, 100ug/ml P	Absolute concentration method, BACTEC MGIT 960	241/302	1/0	574Ser/Leu rpoB	0	17360809	284	0
269	1908c	150	INH	katG			Zenteno-Cuevas R MemInstOswaldCruz 2009			933	SNP	C	G	311	311	Asp/Glu		2007		Mexico	Sequencing	codon 240-390 of katG	HREZ	N.S.	BACTEC 460	17/25	1/0	katG S315T	0	19547874	285	0
270	1908c	151	INH	katG			Bostanabad SZ Tuberk Torak 2007			942	SNP	C	A	314	314	Ser/Asn		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	286	0
271	1908c	152	INH	katG			Bostanabad SZ Tuberk Torak 2007			942	SNP	C	G	314	314	Ser/Thr		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	287	0
273	1908c	154	INH	katG			Marttila HJ AAC 1996	Hazbon MH AAC 2006		944	SNP	AGC	CTA	315	315	Ser/Leu		1989-1995	Clinical isolates.	Finland	Sequencing	Whole gene	HS	>1ug/ml	Disk elution method.	17/19	1/0	katG Pro501Ala.	0	8878604	289	0
275	1908c	156	INH	katG			Musser JM JID 1996			945	SNP	G	C	315	315	Ser/Thr													0	8537659	291	10
276	1908c	157	INH	katG			Haas WA AAC 1997	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	945	SNP	G	T	315	315	Ser/Ile		1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Sierra Leone, Lesotho	PCR-RFLP	892 bp central fragment	HRSEth,H			124/212	4/0		1	9210694	292	10
277	1908c	158	INH	katG			Haas WA AAC 1997	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	945	SNP	G	A	315	315	Ser/Asn		1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Gauteng, Sierra leone	PCR-RFLP	890 bp fragment	H,HRE,HR			124/212	9/0		1	9210694	293	10
278	1908c	159	INH	katG			Heym B MolMicro 1995	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	945	SNP	G	C	315	315	Ser/Thr		1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	Mali Ivory coast, France	PCR-SSCP, Sequencing	Whole gene	H	1 in 4 and >5 in 1	Proportional method	34/37	5/0		1	7746145	294	10
279	1908c	160	INH	katG			Marttila HJ AAC 1996	Hazbon MH AAC 2006		945	SNP	C	A	315	315	Ser/Thr		1989-1995	Finland	Finland	Sequencing	Whole gene	HS,HRS	1 ug/ml for I	Disk elution method.	54/56	2/0	nt1501G/C katG in one	1	8878604	295	10
280	1908c	161	INH	katG			Gagneux S PLOS Path 2006			945	SNP	C	G	315	315	Ser/Thr													0	16789833	296	0
281	1908c	162	INH	katG			Lipin MY CMI 2007			945	SNP	C	A	315	315	Ser/Arg		1998-2001	Tula & Serpokov district, Moscow	Russia	Sequencing	nt 872-1568	HRS	1 ug/ml I, 5 ug/ml S, 20ug/ml R	Absolute concentration method	217/217	2/0	335 /GTC katG in one	1	17403134	297	10
282	1908c	163	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	945	SNP	C	G	315	315	Ser/Arg													0	16870753	298	0
284	1908c	165	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		948	SNP	G	A	316	316	Gly/Asp													0	16870753	300	10
286	1908c	167	INH	katG			Zenteno-Cuevas R MemInstOswaldCruz 2009			954	SNP	G	A	318	318	Gly/Val		2007		Mexico	Sequencing	codon 240-390 of katG	HRSEZ	N.S.	BACTEC 460	17/25	1/0	katG S315T	0	19547874	302	0
288	1908c	169	INH	katG			Bostanabad SZ Tuberk Torak 2007			963	SNP	G	A	321	321	Trp/STOP		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	304	0
289	1908c	170	INH	katG			Bostanabad SZ Tuberk Torak 2007			963	SNP	G	T	321	321	Trp/Leu		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	305	0
290	1908c	171	INH	katG			Bostanabad SZ Tuberk Torak 2007			963	SNP	G	C	321	321	Trp/Ser		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	306	0
291	1908c	172	INH	katG			Bostanabad SZ Tuberk Torak 2007			963	SNP	G	T	321	321	Trp/Cys		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	307	0
294	1908c	175	INH	katG			Haas WA AAC 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998		984	SNP	G	T	328	328	Trp/Leu		1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Lesotho, Eastern Cape, Natal, Swaziland, Gauteng	PCR-RFLP	894 bp central fragment of katG	H			124/212	1/0		0	9210694	310	0
295	1908c	176	INH	katG			Boonaiam S CMI 2009			984	SNP	G	C	328	328	Trp/Ser		2005-2006	Molecular Mycology and Mycobacteriology Laboratory	Thailand	Sequencing	Whole gene	MDR	>=1ug/ml for I	Disk elution method	160/170	1/0		0	19486070	311	0
296	1908c	177	INH	katG			Haas WA AAC 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998		984	SNP	G	C	328	328	Trp/Cys		1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Lesotho, Eastern Cape, Natal, Swaziland, Gauteng	PCR-RFLP	894 bp central fragment of katG	H			124/212	1/0		0	9210694	312	0
297	1908c	178	INH	katG			Bostanabad SZ Tuberk Torak 2007			984	SNP	G	T	328	328	Trp/Cys		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	4/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	313	0
300	1908c	181	INH	katG			Rouse DA AAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1005	SNP	T	C	335	335	Ile/Thr													0	8585728	316	0
302	1908c	183	INH	katG			Lee ASG AAC 1999	Hazbon MH AAC 2006		1008	SNP	T	G	336	336	Leu/Arg													0	10428945	318	0
303	1908c	184	INH	katG			Cockerill FR JID 1995			1011	SNP	A	T	337	337	Tyr/Phe		1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	0.25ug/ml	Proportion method			Pro2Ser, Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Asn258Ser, Ala264Thr	0	7798673	319	0
304	1908c	185	INH	katG			Cockerill FR JID 1995			1011	SNP	A	G	337	337	Tyr/Cys		1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	1ug/ml	Proportion method		1/0	Arg429Leu, Trp505Arg, Met609Ile	0	7798673	320	0
305	1908c	186	INH	katG			Morlock GP AAC 2003			1023	SNP	G	C	341	341	Trp/Ser		2003	USA, Brazil, Russia	Brazil	Sequencing	fragment encompassing codons 249 to 342	HEth	5o Eth, >32 I	Microplate alamar blue assay	17/41	1/0	4463S ethA, C(-15)T inhA regulator	0	14638486	321	0
306	1908c	187	INH	katG			Gagneux S PLOS Path 2006			1035	SNP	A	C	345	345	Lys/Thr													0	16789833	322	0
307	1908c	188	INH	katG			Chan RCY JAC 2007			1037	del		G	346	346	Frameshift		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2	0	17360809	323	0
313	1908c	194	INH	katG			Huang WL JCM 2009			1083	SNP	C	A	361	361	Ala/Asp		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	329	0
314	1908c	195	INH	katG			Huang WL JCM 2009			1091	del		T	364	364	Frameshift		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	330	0
315	1908c	196	INH	katG			Huang WL JCM 2009			1134	SNP	T	C	378	378	Leu/Pro		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	331	0
316	1908c	197	INH	katG			Huang WL JCM 2009			1137	SNP	C	T	379	379	Ala/Val		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	332	0
317	1908c	198	INH	katG			Chan RCY JAC 2007			1140	SNP	C	T	380	380	Thr/Ile		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2	0	17360809	333	0
318	1908c	199	INH	katG			Rouse et al MM 1996	Hazbon MH AAC 2006		1143	SNP	A	G	381	381	Asp/Gly	site directed mutagenesis to create mutants.	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S.	n/a			0	8939440	334	0
319	1908c	200	INH	katG			Gagneux S PLOS Path 2006			1152	SNP	T	G	384	384	Leu/Arg													0	16789833	335	0
320	1908c	201	INH	katG			Chan RCY JAC 2007			1170	SNP	C	T	390	390	Thr/Ile		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2	0	17360809	336	0
321	1908c	202	INH	katG			Sekigushi J JCM 2007			1169	ins		CTA	390	390	ins Leu		2007	Japam & Poland	Japan	Sequencing	Whole gene			Proportion method, BACTEC	38/138	2/0		0	17596354	337	0
322	1908c	203	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1179	SNP	T	A	393	393	Ile/Asn													0	10645439	338	0
324	1908c	205	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		1191	SNP	G	A	397	397	Trp/STOP													0	16870753	340	0
325	1908c	206	INH	katG			Huang WL JCM 2009			1202	del		C	401	401	Frameshift		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	341	0
327	1908c	208	INH	katG			Chan RCY JAC 2007			1227	SNP	C	A	409	409	Ala/Asp		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2	0	17360809	343	0
329	1908c	210	INH	katG			Bolotin S JAC 2009			1243	SNP	G	C	414	414	Lys/Asn		1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0		0	19520719	345	0
330	1908c	211	INH	katG			Ghiladi RA J Am Chem Soc 2005			1254	SNP	G	T	418	418	Arg/Leu													0	16173777	346	0
331	1908c	212	INH	katG			Mo L Microb Drug Res 2004			1254	SNP	G	A	418	418	Arg/Gln													0	15650370	347	0
333	1908c	214	INH	katG			Cockerill FR JID 1995			1272	SNP	C	A	424	424	Ala/Glu		1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	<0.12ug/ml	Proportion method		0/1	Gln224Glu and Pro429Ser in katG.	0	7798673	349	0
334	1908c	215	INH	katG			Cockerill FR JID 1995			1272	SNP	C	T	424	424	Ala/Val		1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	>32ug/ml	Proportion method		1/0	8-bp deletion in codon 10 + Ala550Asp in katG.	0	7798673	350	0
337	1908c	218	INH	katG			Zhang M J Clin Microb 2005	Hazbon MH AAC 2006		1313	ins		A	438	438	Frameshift		2005	Clinical isolates	China	IS6110-based RFLP; Sequencing.	Whole gene	H		BACTEC MGIT 960	1/87	1/0	Arg463Leu in katG; also 1 mutation in oxy-ahpC, and 1 in efpA.	0	16272473	353	0
340	1908c	221	INH	katG			Bostanabad SZ Tuberk Torak 2007			1361	SNP	GAG	CGA	454	454	Glu/Arg		2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).	0	18445950	356	0
341	1908c	222	INH	katG			Bolotin S JAC 2009			1371	SNP	G	T	457	457	Ser/Ile		1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0		0	19520719	357	10
342	1908c	223	INH	katG			Hai Hua Lin TubercRespirDis 2007			1386	SNP	T	C	462	462	Ile/Thr		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)	0	2007582629	358	0
343	1908c	224	INH	katG			Heym B MolMicro 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		1389	SNP	G	T	463	463	Arg/Leu													0	7746145	359	0
344	1908c	225	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1431	SNP	G	A	477	477	Trp/STOP													0	10645439	360	0
346	1908c	227	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1455	SNP	G	T	485	485	Gly/Val													0	10645439	362	0
347	1908c	228	INH	katG			Marttila HJ AAC 1996	Hazbon MH AAC 2006		1463	SNP	G	C	488	488	Lys/Asn		1989-1995	Clinical isolates.	Finland	PCR, Sequencing.	Whole gene	H	>1ug/ml	Disk elution method.	17/19	1/0	katG Gln295STOP	0	8878604	363	0
350	1908c	231	INH	katG			Hai Hua Lin TubercRespirDis 2007			1506	SNP	A	T	502	502	Gln/His		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)	0	2007582629	366	0
351	1908c	232	INH	katG			Abe C JCM 2008			1515	SNP	G	C	505	505	Trp/Ser		Published in 2008		Japan	Sequencing	Whole gene	H		MGIT 960	96/96	1/0		0	18508939	367	0
358	1908c	239	INH	katG			Marttila HJ AAC 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1575	SNP	A	C	525	525	Gln/Pro		1989-1995	Finland	Finland	Sequencing	Whole gene	H	0.4 ug/ml for I	disk elution method	54/56	1/0		0	8878604	374	0
360	1908c	241	INH	katG			Cockerill FR JID 1995			1650	SNP	C	A	550	550	Ala/Asp		1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	0.12->32ug/ml	Proportion method			R strain also Ala424Val; S strain also Gln224Glu,  Ala243Ser.	0	7798673	376	0
361	1908c	242	INH	katG			Hai Hua Lin TubercRespirDis 2007			1653	SNP	C	G	551	551	Ala/Gly		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	None	0	2007582629	377	0
362	1908c	243	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		1667	del		C	556	556	Frameshift	Primary paper not found.												0	16870753	378	0
363	1908c	244	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1701	SNP	T	C	567	567	Phe/Ser													0	10645439	379	0
365	1908c	246	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		1722	SNP	C	A	574	574	Ala/Glu													0	16870753	381	0
366	1908c	247	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1722	SNP	C	T	574	574	Ala/Val													0	10645439	382	0
369	1908c	250	INH	katG			Marttila HJ AAC 1996	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	1761	SNP	T	C	587	587	Leu/Pro		1989-1995	Finland	Finland	Sequencing	Whole gene	H	0.4ug/ml	disk elution method	54/56	1/0		0	8878604	385	0
371	1908c	252	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	1779	SNP	G	A	593	593	Gly/Asp													0	10645439	387	10
374	1908c	255	INH	katG			Marttila HJ AAC 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998		1850	ins		AC	617	617	Frameshift		1989-1995	Finland	Finland	Sequencing	Whole gene	H	1 ug/ml	disk elution method	54/56	1/0		0	8878604	390	0
375	1908c	256	INH	katG			Wei CJ AAC 2003	Ramaswamy S Musser JM Tubercle lung Dis 1998		1857	SNP	T	C	619	619	Leu/Pro	Site directed mutagenesis	2003											0	12543676	391	0
378	1908c	259	INH	katG			Gagneux S PLOS Path 2006			1908	SNP	C	A	636	636	Ala/Glu													0	16789833	394	0
379	1908c	260	INH	katG			Gagneux S PLOS Path 2006			1959	SNP	T	C	653	653	Leu/Pro													0	16789833	395	0
381	1908c	262	INH	katG			Pretorius GS AAC 1995			2085	SNP	A	C	695	695	Asp/Ala		1995	USA,South Africa, Switzerland	South Africa	PCR-SSCP, Sequencing		HRS	40	Agar dilution method	39/69	1/0		0	8619582	397	0
382	1908c	263	INH	katG			Baker LV AAC 2005			2097	SNP	G	A	699	699	Gly/Gln		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0		0	15793126	398	0
384	1908c	265	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	2130	SNP	T	C	710	710	Val/Ala													0	10645439	400	0
386	1908c	267	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		2151	SNP	A	C	717	717	Gln/Pro													0	16870753	402	0
388	1908c	269	INH	katG			Ramaswamy SV J Med Micro 2004			2181	SNP	C	A	727	727	Ala/Asp		1996-1998	Jose Gonzalez Hospital Mexica	Mexico	Directed Oligonucleotide array,  Sequencing	codon 228-357	HRS	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	Ser450Leu rpoB, nt491C/T rrs, Met306Ile embB	0	14729930	404	0
390	1908c	271	INH	katG			Gagneux S PLOS Path 2006			2204	del		GAC	735	735	del Asp													0	16789833	406	0
392	1908c	273	INH	katG			Wei CJ AAC 2003	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	2205	SNP	A	C	735	735	Asp/Ala	Site directed mutagenesis	2003											0	12543676	408	0
394	2245	2	INH	kasA			Ramaswamy SV AAC 2003			231	SNP	G	A	77	77	Met/Ile		2004	Jose Gonzalez tuberculosis clinic in Mexico	Mexico									0	12654653	410	0
395	2245	3	INH	kasA			Lee ASG AAC 1999			363	SNP	G	A	121	121	Arg/Lys		1994-1996	Central Tuberculosis Lab, Singapore	Singapore	Sequencing	Whole gene	H	0.1ug/ml	BACTEC 460	160/192	1/0	present but not mentioned	0	10428945	411	0
398	2245	6	INH	kasA			Lee ASG AAC 1999			1161	SNP	G	A	387	387	Gly/Asp		1994-1996	Central Tuberculosis Lab, Singapore	Singapore	Sequencing	Whole gene	H	0.1ug/ml	BACTEC 460	160/192	1/0	present but not mentioned	0	10428945	414	0
399	2245	7	INH	kasA			Mdluli K Science 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1240	SNP	C	A	413	413	Phe/Leu		1998			Sequencing	Whole gene	H	0.1ug/ml		28/71	1/0	not mentioned	0	9616124	415	0
401	1854c	2	INH	ndh			Cardoso RF Mem Inst Oswaldo Cruz 2007			54	SNP	T	C	18	18	Val/Ala		2006	Institute Adofe Lutz of Ribeirao Preto, Sorocaba, Institute Clemente Ferreira, Sao Paulo and Clinical Bacteriology Lab Parana	Brazil	Sequencing	Whole gene	H	32ug/ml	Microplate alamar blue assay	24/36	1/0	insA at nt17 katG	0	17294000	417	0
403	1854c	4	INH	ndh			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		717	SNP	T	C	239	239	Leu/Pro	Primary paper not found.												0	16870753	419	0
404	1854c	5	INH	ndh			Lee ASG AAC 2001	Hazbon MH AAC 2006		804	SNP	G	A	268	268	Arg/His		1994-1996	Central Tuberculosis Laboratory, Singapore General Hospital	Singapore	Sequencing	Whole gene	H		BACTEC 460	84/106	7/0		0	11408244	420	0
405	2427A	1	INH	oxyR			Sreevatsan S AAC 1997  (*)	Hazbon MH AAC 2006		329	SNP	A	C	110	110		M Microti, M Bovis, M Africanum MTB studied here	1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene	H		Proportion method, BACTEC 460	70/181	only in susceptible	not mentioned	0	9056000	421	0
406	2427A	2	INH	oxyR			Sreevatsan S AAC 1997  (*)	Hazbon MH AAC 2006		323	SNP	G	T	108	108		M Microti, M Bovis, M Africanum MTB studied here	1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene	H		Proportion method, BACTEC 460	70/181	1/0	not mentioned	0	9056000	422	0
407	2427A	3	INH	oxyR			Sreevatsan S Escalante P JCM 1996  (*)	Hazbon MH AAC 2006		284	SNP	G	A	95	95		M Microti, M Bovis, M Africanum MTB studied here. Author found that this polymorphism uniformly differentiated Mbovis(adenine) from non Mbovis(guanine)    using DNA sequencing all 29 Mbovis had adenine at this position and 76 non Mbovis did not. Using RFLP for 255 isolates again same association confirmed	1996		Brazil, Chile, Ecuador, India, Trinidad-Tobago, Mongolia, Romania, Yugoslavia, Spain, Israel, Turkey, Guinea, Algeria, Kenya, Zaire, Somalia,  Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	410 bp of oxyR							0	8818900	423	0
408	2427A	4	INH	oxyR			Sreevatsan S AAC 1997  (*)	Hazbon MH AAC 2006		65	ins		GGCG	22	22	Frameshift	M Microti, M Bovis, M Africanum MTB studied here	1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene			Proportion method, BACTEC 460	70/181	N.S.	not mentioned	0	9056000	424	0
409	2427A	5	INH	oxyR			Sreevatsan S AAC 1997  (*)	Hazbon MH AAC 2006		35	SNP	C	T	12	12		M Microti, M Bovis, M Africanum MTB studied here	1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene			Proportion method, BACTEC 460	70/181	N.S.	not mentioned	0	9056000	425	0
410	2427A	6	INH	oxyR			Lee ASG AAC 1999			26	SNP	C	A	9	9			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	mostly S315T katG or inhA promoter mutation	0	10428945	426	0
411	2427A	7	INH	oxyR			Lee ASG AAC 1999			26	SNP	G	T	9	9			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	mostly S315T katG or inhA promoter mutation	0	10428945	427	0
412	2427A	8	INH	oxyR			Lee ASG AAC 1999	Hazbon MH AAC 2006		17	SNP	G	A	6	6			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	39814	mostly S315T katG or inhA promoter mutation	0	10428945	428	0
413	2428	1	INH	ahpC			Rindi L Int J Tuberc Lung Dis 2005			-223	SNP	G	A	-74	-74			1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 583-819	36H,9MDR	0.1ug/ml	BACTEC 460	45/45	1/0	not mentiond	0	15675557	429	10
414	2428	2	INH	ahpC			Huang WL JCM 2009			-199	SNP	G	A	-66	-66			2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	2/0	not mentiond	0	19494067	430	10
415	2428	3	INH	ahpC			Rindi L Int J Tuberc Lung Dis 2005			-163	SNP	C	T	-54	-54			1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 583-819	36H,9MDR	0.1ug/ml	BACTEC 460	45/45	1/0	not mentiond	0	15675557	431	10
416	2428	4	INH	ahpC			Gagneux S PLOS Path 2006			-54	ins		ATGT	-54	-54														0	16789833	432	0
417	2428	5	INH	ahpC			No Publication Listed			-157	SNP	C	T	-52	-52		Primary paper not found.												0		433	10
418	2428	6	INH	ahpC			Doustdar F MDR 2008			-148	SNP	T	G	-49	-49			2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	None	0	19090721	434	0
419	2428	7	INH	ahpC			Ramaswamy SV AAC 2003			-145	SNP	G	A	-48	-48														0	12654653	435	10
420	2428	8	INH	ahpC			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-139	SNP	G	A	-46	-46			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	oxyRahpC intergenic region	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA  mutation	1	10428945	436	10
421	2428	9	INH	ahpC			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		-46	del		G	-46	-46		Primary paper not found.												0	16870753	437	0
422	2428	10	INH	ahpC			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		-136	SNP	C	T	-45	-45		Primary paper not found.												0	10645439	438	10
423	2428	11	INH	ahpC			Sreevatsan S AAC 1997  (*)	Ramaswamy S Musser JM Tubercle lung Dis 1998		-133	SNP	T	A	-44	-44			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	oxyRahpC intergenic region			Proportion method, BACTEC 460	70/169	1/0	katG deletion	0	9056000	439	0
424	2428	12	INH	ahpC			Silva MS JCM 2003			-121	SNP	T	C	-40	-40			1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	oxyRahpC intergenic region	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportion method	69/69	1/0	S315T kat G	0	12958298	440	0
425	2428	13	INH	ahpC			Silva MS JCM 2003	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-118	SNP	C	T	-39	-39			1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	oxyRahpC intergenic region	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportion method	69/69	2/0	none	1	12958298	441	10
426	2428	14	INH	ahpC			Baker LV AAC 2005	Ramaswamy S Musser JM Tubercle lung Dis 1998		-103	SNP	T	A	-34	-34			1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	oxyRahpC intergenic region	H,HS,HE,HSE,MDR	ratio>=1	Resistance ratio method	202/378	1/0	Arg463Leu katG	0	15793126	442	0
427	2428	15	INH	ahpC			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		-103	SNP	T	C	-34	-34		Primary paper not found.												0	10645439	443	0
428	2428	16	INH	ahpC			Baker LV AAC 2005			-34	del		T	-34	-34			1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	oxyR'-ahpC intergenic region	H,HS,HE,HSE,MDR	ratio>=1	Resistance ratio method	202/378	1/0	S315T, Arg463Leu katG	0	15793126	444	0
429	2428	17	INH	ahpC			Sreevatsan S AAC 1997  (*)	Ramaswamy S Musser JM Tubercle lung Dis 1998		-97	SNP	G	A	-32	-32			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	oxyRahpC intergenic region	H		BACTEC 460 radiometric method or Proportion method for MTB and Mafricanum isolates only	70/169	1/0	none	0	9056000	445	10
430	2428	18	INH	ahpC			Huang WL JCM 2009			-97	SNP	C	T	-32	-32			2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	446	10
431	2428	19	INH	ahpC			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-91	SNP	C	T	-30	-30			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	oxyRahpC intergenic region	H	0.1ug/ml	BACTEC 460	160/192	2/0	katG del/mut or inhA mut	0	10428945	447	10
432	2428	20	INH	ahpC			Baker LV AAC 2005			-61	SNP	C	T	-20	-20			1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	oxyRahpC intergenic region	H,HS,HE,HSE,MDR	ratio>=1	resistance ratio method	202/378	1/0	none	0	15793126	448	10
433	2428	21	INH	ahpC			Gagneux S PLOS Path 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-46	SNP	C	T	-15	-15		Primary paper not found.												0	16789833	449	10
434	2428	22	INH	ahpC			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-37	SNP	C	T	-12	-12			1994-1996	Singapore Gnereal Hospital Pathology Lab										0	10428945	450	10
435	2428	23	INH	ahpC			Gagneux S PLOS Path 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-31	SNP	C	A	-10	-10		Primary paper not found.												0	16789833	451	0
436	2428	24	INH	ahpC			Gagneux S PLOS Path 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-31	SNP	C	T	-10	-10														0	16789833	452	10
437	2428	25	INH	ahpC			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		-31	SNP	C	G	-10	-10		Primary paper not found.												0	16870753	453	0
438	2428	26	INH	ahpC			Silva MS JCM 2003	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-28	SNP	G	A	-9	-9			1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	Promoter region of ahpC	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportionmethod on Ogawa medium	69/69	1/0	none	0	12958298	454	10
439	2428	27	INH	ahpC			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon et al 2006	-19	SNP	G	A	-6	-6			1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA mut	0	10428945	455	10
440	2428	28	INH	ahpC			Huang WL JCM 2009			-16	SNP	G	A	-5	-5			2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	456	10
441	2428	29	INH	ahpC			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		-13	SNP	A	G	-4	-4		Primary paper not found.												0	10645439	457	0
442	2428	30	INH	ahpC			Huang WL JCM 2009			-4	ins		A	-4	-4			2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond	0	19494067	458	0
443	2428	31	INH	ahpC			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		-4	ins		T	-4	-4		Primary paper not found.												0	16870753	459	0
444	2428	32	INH	ahpC			Gagneux S PLOS Path 2006			-1	SNP	T	C	0	0														0	16789833	460	0
447	2428	35	INH	ahpC			Lee ASG AAC 1999	Hazbon MH AAC 2006		15	SNP	C	T	5	5	Thr/Ile		1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA mut	0	10428945	463	0
452	2428	40	INH	ahpC			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		573	SNP	T	G	191	191	Leu/Arg													0	16870753	468	0
453	1483	1	INH	mabA, fabG1			Ramaswamy SV AAC 2003	Hazbon MH AAC 2006		-442	SNP	G	T	-147	-147		Primary paper not found. Mutation is in Rv1482c/ TBFG 11511 Hypothetical protein Rv1482c Asp3Tyr (GAT/TAT)												0	12654653	469	0
454	1483	2	INH	mabA, fabG1			Lee ASG AAC 1999			-277	SNP	A	T	-92	-92			1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG or ahpC-oxyR mut	0	10428945	470	0
455	1483	3	INH	mabA, fabG1			Doustdar F MDR 2008			-202	SNP	G	C	-67	-67			2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	inhA 40 G/C and ahpC -6 G/A	0	19090721	471	0
456	1483	4	INH	mabA, fabG1			Rindi L Int J Tuberc Lung Dis 2005	Ramaswamy S Musser JM Tubercle lung Dis 1998		-73	SNP	G	T	-24	-24			1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 56-303				45/45	1/0	not mentioned	0	15675557	472	0
457	1483	5	INH	mabA, fabG1			Rouse DA AAC 1995			-73	SNP	G	T	-24	-24		site directed mutagenesis,	1995	WashingtonD.C, Bethesda, South Korea		PCR SSCP analysis,	N.S.	HS	0.2ug/ml I, 4ug/mlS	Absolute concentration method	26/26	1/0	R463l katG	0	8585728	473	0
458	1483	6	INH	mabA, fabG1			Baker LV AAC 2005			-73	SNP	G	T	-24	-24		Error in paper? Nt at -24 is G, not T (see Rouse 1995, Rindi 2005)	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	inhA promoter region	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	S315T Arg463Leu in katG, -46G/A in oxyRahpc intergenic region	0	15793126	474	0
459	1483	7	INH	mabA, fabG1			Morlock GP AAC 2003	Hazbon MH AAC 2006		-52	SNP	G	T	-17	-17			2003	USA CDC, Brazil, Russia	USA	Sequencing	284 bp of inhA promoter and nt 13-379 of inhA	HEth	100ug/ml E, 8 ug/ml I	Proportion method	41/42	1/0	I21T inhA ORF	0	14638486	475	0
460	1483	8	INH	mabA, fabG1			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		-49	SNP	A	G	-16	-16		Primary paper not found.												0	10645439	476	0
461	1483	9	INH	mabA, fabG1			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-46	SNP	C	T	-15	-15			1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1UG/ML	BACTEC 460 radimetric method	160/192	43/0	katG or ahpC-oxyR mut	0	10428945	477	0
462	1483	10	INH	mabA, fabG1			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		-34	SNP	A	T	-11	-11		Primary paper not found.												0	16870753	478	0
463	1483	11	INH	mabA, fabG1			Lee ASG AAC 1999	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	-25	SNP	T	A	-8	-8			1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1UG/ML	BACTEC 460 radimetric method	160/192	1/0	katG or ahpC-oxyR mut	0	10428945	479	0
464	1483	12	INH	mabA, fabG1			Baker LV AAC 2005	Hazbon MH AAC 2006		-25	SNP	T	C	-8	-8			1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Promoter region of inhA	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	none	0	15793126	480	0
465	1483	13	INH	mabA, fabG1			Rouse DA AAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		-25	SNP	T	G	-8	-8		site directed mutagenesis,	1995	WashingtonD.C, Bethesda, South Korea		PCR SSCP analysis	not specified	H	0.2ug/ml	Absolute concentration method	39990	1/0	none	0	8585728	481	0
466	1483	14	INH	mabA, fabG1			Sekigushi J JCM 2007			-16	SNP	T	A	-5	-5			2007	Japan & Poland		Sequencing	nt-217 to -198, 1145-1126			Proportion method, BACTEC	38/138	1/0	M257T R463L katG	0	17596354	482	0
470	1484	1	INH	inhA			Hai Hua Lin TubercRespirDis 2007			25	SNP	A	C	8	8	Lys/Asn		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)	0	2007582629	486	0
471	1484	2	INH	inhA			Basso L JID 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		48	SNP	T	C	16	16	Ile/Thr		1998		USA	Sequencing	Whole gene	H	1.0ug/ml	BACTEC	N.S.	1/0	none	0	9728546	487	0
473	1484	4	INH	inhA			Morlock GP AAC 2003	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	63	SNP	T	C	21	21	Ile/Thr		2003	USA CDC, Brazil, Russia	USA	Sequencing	284 bp inhA promoter and nt 13-379 of inhA	HEth	>32ug/ml, 8ug/ml I, >200 ug/ml or 100ug/ml Eth	Proportion method	41/42	3/0	C(-15)T, G(-17)T inhA regulator,	0	14638486	489	0
474	1484	5	INH	inhA			Basso L JID 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	141	SNP	T	C	47	47	Ile/Thr		1998		USA	Sequencing	Whole gene	H	1.0 ug/ml	BACTEC	N.S.	1/0	none	0	9728546	490	0
475	1484	6	INH	inhA			Basso L JID 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		234	SNP	T	C	78	78	Val/Ala		1998		USA	Sequencing	Whole gene	H	1.0 ug/ml	BACTEC	N.S.	1/0	none	0	9728546	491	0
477	1484	8	INH	inhA			Vilcheze C Nat Med 2006	Hazbon MH AAC 2006		282	SNP	C	T	94	94	Ser/Leu	Using linkage transduction showed that S94A confers resistance to INH by decreased binding to INH-NAD inhibitor												0	16906155	493	0
479	1484	10	INH	inhA			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		285	SNP	T	C	95	95	Ile/Thr	Primary paper not found. CouldnÆt locate mutant. The figure in the reference paper only shows I95P not I95T												0	10645439	495	0
480	1484	11	INH	inhA			Leung ET AAC 2006	Hazbon MH AAC 2006		582	SNP	T	C	194	194	Ile/Thr		1999-2002	HongKong, South China	Hong Kong, China	Sequencing	-38 to-13, 250-268,381-399,510-492,860-840,	H	>1ug/ml	Proportion method	102/375	1/0	not mentioned	0	16495272	496	0
489	0342	3	INH	iniA			Ramaswamy SV AAC 2003			1611	SNP	G	A	537	537	Arg/His		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	505	0
491	1592c	1	INH	Rv1592c			Ramaswamy SV AAC 2003			-88	SNP	G	A	-29	-29			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	507	0
492	1592c	2	INH	Rv1592c			Ramaswamy SV AAC 2003			126	SNP	C	T	42	42	Pro/Leu		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	508	0
493	1592c	3	INH	Rv1592c			Ramaswamy SV AAC 2003			1290	SNP	T	C	430	430	Val/Ala					Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	509	0
495	2242	1	INH	srmR homolog			Ramaswamy SV AAC 2003			9	SNP	A	G	3	3	Asp/Gly		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	511	0
496	2242	2	INH	srmR homolog			Ramaswamy SV AAC 2003			969	SNP	T	C	323	323	Met/Thr		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	512	0
497	2243	1	INH	fabD, mtFabD			Ramaswamy SV AAC 2003			825	SNP	G	A	275	275	Ser/Asn		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	513	0
498	2247	1	INH	accD6			Ramaswamy SV AAC 2003			687	SNP	A	G	229	229	Asp/Gly		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	514	0
499	0129c	1	INH	fbpC, 85C, fbpC2, mpt45			Ramaswamy SV AAC 2003			-190	SNP	C	T	-63	-63			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	515	0
502	0129c	2	INH	fbpC, 85C, fbpC2, mpt45			Ramaswamy SV AAC 2003			-70	SNP	A	C	-23	-23			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	518	0
503	2846c	1	INH	efpA			Ramaswamy SV AAC 2003			219	SNP	T	C	73	73	Ile/Thr		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	519	0
504	3566c	1	INH	nhoA, nat			Ramaswamy SV AAC 2003			202	SNP	C	T	67	67	Gly/Arg		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	520	0
505	3566c	2	INH	nhoA, nat			Ramaswamy SV AAC 2003			621	SNP	G	A	207	207	Gly/Glu		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				0	12654653	521	0
506	3919c	1	SM	gid, gidB			Okamoto S MolMicro 2007			48	SNP	C	G	16	16	Leu/Arg		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	HRSE	20 ug/ml	Absolute concentration method	57/132	1/0	G257C(rpsL)	0	17238915	522	0
507	3919c	2	SM	gid, gidB			Okamoto S MolMicro 2007			101	del		G	34	34	Frameshift		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R,H,S,E,K,PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB); A908G (rrs)	0	17238915	523	0
508	3919c	3	SM	gid, gidB			Okamoto S MolMicro 2007			116	del		C	39	39	Frameshift		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S	20 ug/ml	Absolute concentration method	57/132	1/0	none	0	17238915	524	0
509	3919c	4	SM	gid, gidB			Okamoto S MolMicro 2007			119	SNP	G	T	40	40	Glu/STOP		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	H, SM, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A262C(rpsL)	0	17238915	525	0
510	3919c	5	SM	gid, gidB			Okamoto S MolMicro 2007			140	SNP	G	A	47	47	Arg/Gln		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A908G(rrs)	0	17238915	526	0
511	3919c	6	SM	gid, gidB			Okamoto S MolMicro 2007			164	SNP	T	G	55	55	Ile/Ser		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB), A513C (rrs)	0	17238915	527	0
512	3919c	7	SM	gid, gidB			Okamoto S MolMicro 2007			200	SNP	G	C	67	67	Asp/His		After 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	S	8 ug/ml	Absolute concentration method	57/132	1/0	none	0	17238915	528	0
513	3919c	8	SM	gid, gidB			Okamoto S MolMicro 2007			209	SNP	A	C	70	70	Ser/Arg		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB); A513C (rrs)	0	17238915	529	0
514	3919c	9	SM	gid, gidB			Okamoto S MolMicro 2007			209	SNP	C	A	70	70	Ser/Arg		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	none	0	17238915	530	0
515	3919c	10	SM	gid, gidB			Okamoto S MolMicro 2007			212	SNP	G	T	71	71	Gly/Val		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E,	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB)	0	17238915	531	0
516	3919c	11	SM	gid, gidB			Okamoto S MolMicro 2007			224	SNP	C	G	75	75	Pro/Ala		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	H, S, E, K	20 ug/ml	Absolute concentration method	57/132	1/0	none	0	17238915	532	0
517	3919c	12	SM	gid, gidB			Spies FS AAC 2008			135	SNP	G	C	45	45	Trp/Cys		Published 2008	Rio Grande do Sul	Brazil	Sequencing	675bp fragment	H,R,S,E	15,6 ug/ml	Resazurin microtiter assay	47/32	1/0	none	0	18541729	533	0
518	3919c	12	SM	gid, gidB			Okamoto S MolMicro 2007			276	SNP	A	C	92	92	Glu/Asp		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A128G(rpsL)	0	17238915	534	0
519	3919c	13	SM	gid, gidB			Okamoto S MolMicro 2007			308	SNP	G	T	103	103	Glu/STOP			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E	N.S	Absolute concentration method	57/132	1/0	A513C (rrs)	0	17238915	535	0
520	3919c	14	SM	gid, gidB			Okamoto S MolMicro 2007			350	del		G	117	117	Frameshift		After 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	S	8ug/ml	Absolute concentration method	57/132	2/0		0	17238915	536	0
521	3919c	15	SM	gid, gidB			Okamoto S MolMicro 2007			374	SNP	C	T	125	125	Gln/STOP			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0		0	17238915	537	0
522	3919c	16	SM	gid, gidB			Okamoto S MolMicro 2007			380	SNP	A	C	127	127	Gln/Pro			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0		0	17238915	538	0
523	3919c	17	SM	gid, gidB			Okamoto S MolMicro 2007			401	SNP	C	A	134	134	Ala/Glu			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0		0	17238915	539	0
524	3919c	18	SM	gid, gidB			Okamoto S MolMicro 2007			413	SNP	C	T	138	138	Ala/Glu			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0		0	17238915	540	0
526	3919c	19	SM	gid, gidB			Okamoto S MolMicro 2007			548	SNP	C	A	183	183	Ala/Glu			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0		0	17238915	542	0
527	3919c	20	SM	gid, gidB			Okamoto S MolMicro 2007			563	SNP	T	G	188	188	Val/Gly			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	a276C (gidB), G888A (rrs)	0	17238915	543	0
528	3919c	21	SM	gid, gidB			Okamoto S MolMicro 2007			599	SNP	C	A	200	200	Ala/Glu			132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0		0	17238915	544	0
529	0682	1	SM	rpsL			Sreevatsan S AAC 1996			27	SNP	G	A	9	9	Arg/His													0	8849220	545	0
530	0682	2	SM	rpsL			Brzostek A IntJ TubLungDis 2004			120	SNP	C	T	40	40	Thr/Ile	novel missense mutation	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	4/88	4/0		0	15305490	546	0
531	0682	3	SM	rpsL			Brzostek A IntJ TubLungDis 2004			123	SNP	C	G	41	41	Thr/Ser		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr41Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly84Val, Arg86Trp, Val87Leu	0	15305490	547	0
532	0682	4	SM	rpsL			Nair J Mol Micro 1993	Musser J CMRev 1995		129	SNP	A	G	43	43	Lys/Arg		1950		USA	Sequencing	Whole gene	S, H, E	N.S	N.S	40033	1/0		1	7968530	548	28
533	0682	5	SM	rpsL			Finken M Mol Micro 1993			129	SNP	A	C	43	43	Lys/Thr	mutations in rpsL at codon 43 and 88 present in 20 of 38 STR-res., none of STR-suscept. 9 of 18 STR-res strains had mutations at 513 or 516 of rrs	1993	m. luteus, m.tb		Sequencing	Whole gene	MDR	N.S	Proportion method, BACTEC 460	38/73	5/0	not specified	0	7934937	549	0
534	0682	6	SM	rpsL			Brzostek A IntJ TubLungDis 2004			154	SNP	G	C	51	51	Lys/Asn		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr51Ser is one of 18 silent mutations and 6 a.a. sub: Lys41Asn, Val52Gly, Gly84Val, Arg86Trp, Val87Leu	0	15305490	550	0
535	0682	7	SM	rpsL			Brzostek A IntJ TubLungDis 2004			156	SNP	T	G	52	52	Val/Gly		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr52Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val41Gly, Gly84Val, Arg86Trp, Val87Leu	0	15305490	551	0
536	0682	8	SM	rpsL			Brzostek A IntJ TubLungDis 2004			252	SNP	G	T	84	84	Gly/Val		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr84Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly41Val, Arg86Trp, Val87Leu	0	15305490	552	0
538	0682	10	SM	rpsL			Okamoto S MolMicro 2007			258	SNP	G	C	86	86	Arg/Pro		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing		RHSE	20 ug/ml	Absolute concentration method	57/132	1/0	T47G (gidB)	0	17238915	554	0
541	0682	13	SM	rpsL			Finken M Mol Micro 1993			264	SNP	A	G	88	88	Lys/Arg	mutations in rpsL at codon 43 and 88 present in 20 of 38 STR-res., none of STR-suscept. 9 of 18 STR-res strains had mutations at 513 or 516 of rrs	1993	m. luteus, m.tb		Sequencing	Whole gene	S	N.S	Proportion method	38/73	2/0	n/a	1	7934937	557	28
542	0682	14	SM	rpsL			Katsukawa C J Appl Micro 1997			264	SNP	A	T	88	88	Lys/Met													0	9418025	558	0
543	0682	15	SM	rpsL			Katsukawa C J Appl Micro 1997			264	SNP	A	C	88	88	Lys/Thr													0	9418025	559	0
545	2043c	1	PZA	pncA			Marttila HJ AAC 1999			-37	SNP	T	G	-12	-12		*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	561	0
546	2043c	2	PZA	pncA			Scorpio A AAC 1997			-34	SNP	A	C	-11	-11		*PZA-res mutant made in vitro	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	562	0
547	2043c	3	PZA	pncA			Sreevatsan S AAC 1997			-34	SNP	A	G	-11	-11			1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0		1	9056006	563	10
548	2043c	4	PZA	pncA			Morlock GP AAC 2000			-22	SNP	T	C	-7	-7			1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0		0	11083630	564	0
551	2043c	7	PZA	pncA			Portugal I AAC 2004			3	SNP	T	C	1	1	Met/Thr		2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55		0	10449496	567	0
552	2043c	8	PZA	pncA			Lee KW J Korean Med Sci 2001			3	SNP	G	T	1	1	Met/Ile	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	568	0
554	2043c	10	PZA	pncA			Sekiguchi JI JCM 2007			9	SNP	C	A	3	3	Ala/Glu		2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0		0	17596354	570	10
555	2043c	11	PZA	pncA			Lee KW J Korean Med Sci 2001			12	SNP	T	G	4	4	Leu/Trp	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	571	0
556	2043c	12	PZA	pncA			Morlock GP AAC 2000			12	SNP	T	C	4	4	Leu/Ser		1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0		0	11083630	572	0
557	2043c	13	PZA	pncA			Scorpio A AAC 1997			15	SNP	T	G	5	5	Ile/Ser	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	573	0
560	2043c	16	PZA	pncA			Hirano  K TLD 1997			21	SNP	T	G	7	7	Val/Gly	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0		0	9692180	576	20
561	2043c	17	PZA	pncA			Lee KW J Korean Med Sci 2001			21	SNP	T	A	7	7	Val/Asp	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	577	0
563	2043c	19	PZA	pncA			Lee KW J Korean Med Sci 2001			24	SNP	A	G	8	8	Asp/Gly	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	579	10
564	2043c	20	PZA	pncA			Scorpio A AAC 1997			24	SNP	C	G	8	8	Asp/Glu	*PZA-res mutant made in vitro	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	580	0
565	2043c	21	PZA	pncA			Lee KW J Korean Med Sci 2001			27	SNP	T	C	9	9	Val/Ala	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	581	10
566	2043c	22	PZA	pncA			Lee KW J Korean Med Sci 2001			27	SNP	T	G	9	9	Val/Gly	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	582	20
569	2043c	25	PZA	pncA			Scorpio A AAC 1997			29	del		C	10	10	Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	585	0
572	2043c	28	PZA	pncA			Cheng SJ AAC 2000			30	SNP	G	A	10	10	Gln/Arg		1990-1992		USA	Sequencing	Whole gene	ZHREO	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	588	0
573	2043c	29	PZA	pncA			Hirano  K TLD 1997			30	SNP	A	C	10	10	Gln/Pro	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0		1	9692180	589	20
574	2043c	30	PZA	pncA			Morlock GP AAC 2000			30	SNP	G	A	10	10	Gln/Pro		1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0		0	11083630	590	0
576	2043c	32	PZA	pncA			Scorpio A AAC 1997			36	SNP	A	C	12	12	Asp/Ala	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		1	9055989	592	10
577	2043c	33	PZA	pncA			Lemaitre N AAC 1999			39	SNP	T	C	13	13	Phe/Ser	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1987		France	Sequencing	Whole gene	ZHRES	>2000		19/35	1/0		0	10390238	593	0
580	2043c	36	PZA	pncA			Lee KW J Korean Med Sci 2001			42	SNP	G	A	14	14	Cys/Tyr	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	596	0
581	2043c	37	PZA	pncA			Chan RCY JAC 2007			47	del		G	16	16	Frameshift		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	597	0
582	2043c	38	PZA	pncA			Hirano  K TLD 1997			51	SNP	G	A	17	17	Gly/Asp	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	2/0		1	9692180	598	10
583	2043c	39	PZA	pncA			Chan RCY JAC 2007			51	SNP	G	T	17	17	Gly/Val		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	599	0
584	2043c	40	PZA	pncA			Cheng SJ AAC 2000			50	ins		GG	17	17	Frameshift				USA	Sequencing	Whole gene	ZHR	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	600	0
585	2043c	41	PZA	pncA			Chan RCY JAC 2007			57	SNP	T	G	19	19	Leu/Arg		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	601	20
586	2043c	42	PZA	pncA			Sreevatsan S AAC 1997			57	SNP	T	C	19	19	Leu/Pro		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		1	9056006	602	30
587	2043c	43	PZA	pncA			Chan RCY JAC 2007			63	SNP	T	G	21	21	Val/Gly		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		1	17360809	603	10
588	2043c	44	PZA	pncA			Chan RCY JAC 2007			65	del		A	22	22	Frameshift		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	604	0
589	2043c	45	PZA	pncA			Hou L Epi Infect 2000			59	del		C	20	20	Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRSE	1800	Proportion method, BACTEC 460	35/65	1/0		0	10813147	605	0
590	2043c	46	PZA	pncA			Lee KW J Korean Med Sci 2001			69	SNP	GT	TC	23	23	Gly/Val	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	606	0
591	2043c	47	PZA	pncA			Sreevatsan S AAC 1997			71	del		G	24	24	Frameshift		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	7/0		1	9056006	607	0
592	2043c	48	PZA	pncA			Hou L Epi Infect 2000			71	del		G	24	24	Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRH	600	Proportion method, BACTEC 460	35/65	1/0		1	10813147	608	0
593	2043c	49	PZA	pncA			Lee KW J Korean Med Sci 2001			75	SNP	C	A	25	25	Ala/Glu	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	609	0
594	2043c	50	PZA	pncA			Scorpio A AAC 1997			78	SNP	C	G	26	26	Ala/Gly	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	610	0
595	2043c	51	PZA	pncA			Marttila HJ AAC 1999			83	del		C	28	28	Frameshift	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	611	0
596	2043c	52	PZA	pncA			Lee KW J Korean Med Sci 2001			84	SNP	C	A	28	28	Ala/Asp	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	612	0
599	2043c	55	PZA	pncA			Scorpio A AAC 1997			101	ins		T	34	34	Frameshift	*PZA-res mutant made in vitro	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	615	0
600	2043c	56	PZA	pncA			Hirano  K TLD 1997			102	SNP	A	C	34	34	Tyr/Ser	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0		1	9692180	616	10
601	2043c	57	PZA	pncA			Stavrum R PlosOne 2009			105	SNP	T	C	35	35	Leu/Pro		Published 2009		India	Sequencing	Whole gene			N.S.		1/0		0	19234602	617	30
602	2043c	58	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			105	SNP	T	G	35	35	Leu/Arg		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		1	16848344	618	20
606	2043c	62	PZA	pncA			Hirano  K TLD 1997			123	SNP	C	A	41	41	Tyr/STOP	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0		0	9692180	622	0
607	2043c	63	PZA	pncA			Sreevatsan S AAC 1997			123	SNP	C	G	41	41	Tyr/STOP		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		1	9056006	623	30
608	2043c	64	PZA	pncA			Hirano  K TLD 1997			129	SNP	A	C	43	43	His/Pro	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0		0	9692180	624	10
609	2043c	65	PZA	pncA			Lee KW J Korean Med Sci 2001			135	SNP	T	G	45	45	Val/Gly	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	625	20
610	2043c	66	PZA	pncA			Hirano  K TLD 1997			137	ins		G	46	46	Frameshift	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHE	>800	Proportion method	33/168	1/0		0	9692180	626	0
612	2043c	68	PZA	pncA			Cheng SJ AAC 2000			138	SNP	C	A	46	46	Ala/Glu				South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0		0	10681313	628	0
613	2043c	69	PZA	pncA			Cheng SJ AAC 2000			138	SNP	C	T	46	46	Ala/Val				South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0		1	10681313	629	10
618	2043c	74	PZA	pncA			Lee KW J Korean Med Sci 2001			147	SNP	A	C	49	49	Asp/Ala	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	634	10
619	2043c	75	PZA	pncA			Marttila HJ AAC 1999			147	SNP	A	T	49	49	Asp/Val	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	635	0
620	2043c	76	PZA	pncA			Marttila HJ AAC 1999			147	SNP	A	G	49	49	Asp/Gly	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	636	10
624	2043c	80	PZA	pncA			Hirano  K TLD 1997			153	SNP	A	C	51	51	His/Pro	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0		1	9692180	640	10
625	2043c	81	PZA	pncA			Hirano  K TLD 1997			153	SNP	A	G	51	51	His/Arg	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0		1	9692180	641	10
626	2043c	82	PZA	pncA			Sekiguchi JI JCM 2007			153	SNP	C	G	51	51	His/Gln		2006	TB patients in Japan and Poland	Poland	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0		0	17596354	642	0
627	2043c	83	PZA	pncA			Sekiguchi JI JCM 2007			153	SNP	C	A	51	51	His/Gln		2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	2/0		0	17596354	643	0
629	2043c	85	PZA	pncA			Cheng SJ AAC 2000			159	SNP	A	C	53	53	Asp/Ala				South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0		0	10681313	645	10
630	2043c	86	PZA	pncA			Lee KW J Korean Med Sci 2001			158	del		A	53	53	Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	646	0
632	2043c	88	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			162	SNP	C	T	54	54	Pro/Leu		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		0	16848344	648	0
633	2043c	89	PZA	pncA			Lee KW J Korean Med Sci 2001			161	del		C	54	54	Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	649	0
634	2043c	90	PZA	pncA			Scorpio A AAC 1997			161	ins		T	54	54	Frameshift	*PZA-res mutant made in vitro	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	650	0
635	2043c	91	PZA	pncA			Scorpio A Nature Med 1996			161	del		G	54	54	Frameshift			clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	7H9 liquid medium, pH5.6; PZase activity assayed according to Wayne's method	39910	1/0		0	8640557	651	0
638	2043c	94	PZA	pncA			Brown TJ JMedMicro 2000			171	SNP	A	C	57	57	His/Pro	all sensitive isolates were WT and mutants and resistant ones had mutant genotypes	2000	4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK	Turkey	Sequencing	Whole gene	ZHRP		BACTEC radiometric-based culture method, standard protocol; and PZase activity	13/18	1/0	A2416T (rpoB)	0	10882091	654	10
639	2043c	95	PZA	pncA			Chan RCY JAC 2007			171	SNP	A	T	57	57	His/Leu		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	655	0
640	2043c	96	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			173	del		T	58	58	Frameshift		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		1	16848344	656	0
642	2043c	98	PZA	pncA			Hirano  K TLD 1997			175	SNP	C	G	58	58	Phe/Leu	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	400	Proportion method	33/168	1/0		0	9692180	658	0
646	2043c	102	PZA	pncA			Morlock GP AAC 2000			186	SNP	C	G	62	62	Pro/Arg		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0		0	11083630	662	0
647	2043c	103	PZA	pncA			Chan RCY JAC 2007			186	SNP	C	T	62	62	Pro/Leu		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	663	0
648	2043c	104	PZA	pncA			Hirano  K TLD 1997			189	SNP	A	G	63	63	Asp/Gly	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0		1	9692180	664	10
651	2043c	107	PZA	pncA			Lemaitre N AAC 1999			191	ins		A	64	64	Frameshift	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1996		France	Sequencing	Whole gene	ZSHE	1000ug/ml			1/0		0	10390238	667	0
657	2043c	113	PZA	pncA			Cheng SJ AAC 2000			204	SNP	G	A	68	68	Trp/STOP				USA	Sequencing	Whole gene	Z	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	673	0
658	2043c	114	PZA	pncA			Lee KW J Korean Med Sci 2001			204	SNP	G	C	68	68	Trp/Ser	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	674	0
659	2043c	115	PZA	pncA			Sreevatsan S AAC 1997			204	SNP	G	T	68	68	Trp/Leu		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		1	9056006	675	10
660	2043c	116	PZA	pncA			Scorpio A AAC 1997			207	SNP	C	G	69	69	Pro/Arg	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>300ug/ml	Pzase testing by Wayne's method	46/46	2/0		0	9055989	676	0
661	2043c	117	PZA	pncA			Hou L Epi Infect 2000			207	SNP	C	G	69	69	Pro/Arg		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1200	Proportion method, BACTEC 460	35/65	1/0		0	10813147	677	0
662	2043c	118	PZA	pncA			Lemaitre N AAC 1999			207	SNP	C	T	69	69	Pro/Leu	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1994		France	Sequencing	Whole gene	ZHR	(pH 5.6, 5.8) >2000/>2000		19/35	1/0		0	10390238	678	0
665	2043c	121	PZA	pncA			Morlock GP AAC 2000			213	SNP	A	G	71	71	His/Arg		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0		1	11083630	681	30
666	2043c	122	PZA	pncA			Cheng SJ AAC 2000			213	SNP	T	G	71	71	His/Glu				USA	Sequencing	Whole gene	ZHRS	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	682	0
668	2043c	124	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			216	SNP	G	A	72	72	Cys/Tyr		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		0	16848344	684	0
669	2043c	125	PZA	pncA			Sekiguchi JI JCM 2007			216	SNP	C	G	72	72	Cys/Trp		2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0		0	17596354	685	0
671	2043c	127	PZA	pncA			Sekiguchi JI JCM 2007			218	ins		CGCATTGCCG	73		Frameshift		2006	TB patients in Japan and Poland		Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0		0	17596354	687	0
672	2043c	128	PZA	pncA			Mestdagh M AAC 1999			221	ins		G	74	74	Frameshift	PZase negativity correlated to PZA-R, only 39 of 42 PZase positive test correl. to susceptibility	1999	54 MDR mtb clinical strains	United Kingdom	Sequencing	Whole gene	Z		BACTEC 460	23/62	2/0		0	10471589	688	0
673	2043c	129	PZA	pncA			Chan RCY JAC 2007			225	SNP	T	C	75	75	Met/Thr	36% resistant to PZA, 80% of PZA-r had mutations, 80% mutants had resistance, 11% drug susceptible had mutations	1994-2004	250 drug-res. Mtb from Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZORH	100ug/ml	BACTEC MGIT 960	89/250	1/0	Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB); Ser315Thr(katG)	0	17360809	689	0
675	2043c	131	PZA	pncA			Brown TJ JMedMicro 2000			228	SNP	C	T	76	76	Thr/Ile	all sensitive isolates were WT and mutants and resistant ones had mutant genotypes	2000	4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK	United Kindom, Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460	13/18	8/0	C2431T (rpoB)	0	10882091	691	0
676	2043c	132	PZA	pncA			Morlock GP AAC 2000			234	SNP	G	A	78	78	Gly/Asp		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0		0	11083630	692	10
677	2043c	133	PZA	pncA			Chan RCY JAC 2007			237	SNP	C	G	79	79	Ala/Gly		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	693	0
678	2043c	134	PZA	pncA			Brown TJ JMedMicro 2000			239	del		A	80		Frameshift	all sensitive isolates were WT and mutants and resistant ones had mutant genotypes	2000	4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK	Turkey	Sequencing	Whole gene	Z		BACTEC 460	13/18	1/0	C2431T (rpoB)	0	10882091	694	0
681	2043c	137	PZA	pncA			Cheng SJ AAC 2000			246	SNP	A	G	82	82	His/Arg				USA	Sequencing	Whole gene	ZHRES	300	Proportion method, BACTEC 460	59/59	1/0		1	10681313	697	30
682	2043c	138	PZA	pncA			Rodrigues V de F AAC 2005			246	SNP	A	T	82	82	His/Leu		1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40		0	15616332	698	0
684	2043c	140	PZA	pncA			Mestdagh M AAC 1999			255	SNP	T	G	85	85	Leu/Arg	PZase negativity correlated to PZA-R, only 39 of 42 PZase positive test correl. to susceptibility	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460	23/62	1/0		0	10471589	700	20
685	2043c	141	PZA	pncA			Scorpio A AAC 1997			255	SNP	T	C	85	85	Leu/Pro	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	3/0		1	9055989	701	30
686	2043c	142	PZA	pncA			Lemaitre N AAC 1999			261	SNP	C	T	87	87	Thr/Met	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1987		France	Sequencing	Whole gene	ZHRES	1000-1500		19/35	1/0		0	10390238	702	0
687	2043c	143	PZA	pncA			Hou L Epi Infect 2000			264	SNP	C	A	88	88	Ser/STOP		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRES	>2000	Proportion method, BACTEC 460	35/65	1/0		0	10813147	703	0
688	2043c	144	PZA	pncA			Hannan MM JCM 2001			270	SNP	T	G	90	90	Ile/Ser		1996-1999	isolates from 5 counties in California	USA	Sequencing	Whole gene	Z		BACTEC radiometric testing	39883	1/0		0	11158123	704	0
689	2043c	145	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			270	SNP	T	G	90	90	Ile/Ser		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		0	16848344	705	0
692	2043c	148	PZA	pncA			Peridgao J MDR 2008			285	SNP	C	A	95	95	Tyr/STOP		2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0		0	18573039	708	0
695	2043c	151	PZA	pncA			Scorpio A AAC 1997			288	SNP	A	C	96	96	Lys/Thr	*PZA-res mutant made in vitro	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	711	0
696	2043c	152	PZA	pncA			Hirano  K TLD 1997			287	ins		T	96		Frameshift	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0		0	9692180	712	0
697	2043c	153	PZA	pncA			Lee KW J Korean Med Sci 2001			287	ins		T	96		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	713	0
698	2043c	154	PZA	pncA			Scorpio A AAC 1997			289	SNP	G	T	96	96	Lys/Asn	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		1	9055989	714	10
699	2043c	155	PZA	pncA			Scorpio A Nature Med 1996			287	del		G	96		Frameshift			clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	Z	>500ug/ml	PZase test with Wayne's method	39910	1/0		0	8640557	715	0
701	2043c	157	PZA	pncA			Morlock GP AAC 2000			291	SNP	G	A	97	97	Gly/Asp		1999			Sequencing	Whole gene	Z	400	Proportion method	37/60	1/0		0	11083630	717	10
702	2043c	158	PZA	pncA			Hirano  K TLD 1997			297	SNP	C	A	99	99	Tyr/STOP	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0		0	9692180	718	0
703	2043c	159	PZA	pncA			Morlock GP AAC 2000			297	SNP	C	G	99	99	Tyr/STOP		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	2/0		1	11083630	719	30
704	2043c	160	PZA	pncA			Cheng SJ AAC 2000			299	ins		G	100		Frameshift				South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0		0	10681313	720	0
705	2043c	161	PZA	pncA			Hou L Epi Infect 2000			299	ins		A	100		Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	900	Proportion method, BACTEC 460	35/65	1/0		0	10813147	721	0
707	2043c	163	PZA	pncA			Marttila HJ AAC 1999			306	SNP	C	T	102	102	Ala/Val	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	2/0	not tested	1	10390239	723	10
708	2043c	164	PZA	pncA			Lemaitre N AAC 1999			305	ins		C	102		Frameshift	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1989		France	Sequencing	Whole gene	ZHRES	500-1500		19/35	1/0		0	10390238	724	0
710	2043c	166	PZA	pncA			Lee KW J Korean Med Sci 2001			305	del		TACAG	102		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	726	0
711	2043c	167	PZA	pncA			Lee KW J Korean Med Sci 2001			309	SNP	A	C	103	103	Tyr/Ser	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0		0	11641519	727	10
712	2043c	168	PZA	pncA			Lemaitre N AAC 1999			309	SNP	A	G	103	103	Tyr/Cys	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1994		France	Sequencing	Whole gene	ZHRE	1500			1/0		0	10390238	728	0
713	2043c	169	PZA	pncA			Marttila HJ AAC 1999			309	SNP	C	G	103	103	Tyr/STOP	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	1	10390239	729	30
714	2043c	170	PZA	pncA			Morlock GP AAC 2000			309	SNP	C	A	103	103	Tyr/STOP		1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0		0	11083630	730	0
715	2043c	171	PZA	pncA			Scorpio A AAC 1997			311	del		C	104	104	Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	731	0
716	2043c	172	PZA	pncA			Hirano  K TLD 1997			312	SNP	C	G	104	104	Ser/Arg	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0		1	9692180	732	10
719	2043c	175	PZA	pncA			Cheng SJ AAC 2000			341	del		C	114		Frameshift				South Korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?		0	10681313	735	0
722	2043c	178	PZA	pncA			Marttila HJ AAC 1999			348	SNP	T	G	116	116	Leu/Arg	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	1	10390239	738	20
723	2043c	179	PZA	pncA			Hou L Epi Infect 2000			354	SNP	A	C	118	118	Asn/Thr		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	1000	Proportion method, BACTEC 460	35/65	1/0		0	10813147	739	0
725	2043c	181	PZA	pncA			Stavrum R PlosOne 2009			357	SNP	G	C	119	119	Trp/Cys		Published 2009		India	Sequencing	Whole gene	RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present	0	19234602	741	0
726	2043c	182	PZA	pncA			Lee KW J Korean Med Sci 2001			357	SNP	G	A	119	119	Trp/STOP	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	742	0
727	2043c	183	PZA	pncA			Portugal I AAC 2004			360	SNP	T	C	120	120	Leu/Pro		2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55		0	10449496	743	30
728	2043c	184	PZA	pncA			Sreevatsan S AAC 1997			363	SNP	G	C	121	121	Arg/Pro		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		1	9056006	744	10
729	2043c	185	PZA	pncA			Hou L Epi Infect 2000			368	ins		AG	123		Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1000	Proportion method, BACTEC 460	35/65	1/0		0	10813147	745	0
731	2043c	187	PZA	pncA			Marttila HJ AAC 1999			375	SNP	T	A	125	125	Val/Asp	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	747	0
732	2043c	188	PZA	pncA			Peridgao J MDR 2008			375	SNP	T	G	125	125	Val/Gly		2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	19/0		0	18573039	748	20
734	2043c	190	PZA	pncA			Lee KW J Korean Med Sci 2001			380	del		GG	127		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	750	0
736	2043c	192	PZA	pncA			Lee KW J Korean Med Sci 2001			380	ins		AG	127		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	752	0
737	2043c	193	PZA	pncA			Rodrigues V de F AAC 2005			384	SNP	T	G	128	128	Val/Gly		1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method and Pzase test	59	40		1	15616332	753	20
738	2043c	194	PZA	pncA			Lee KW J Korean Med Sci 2001			386	del		ATGT	129		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	754	0
739	2043c	195	PZA	pncA			Morlock GP AAC 2000			386	ins		GAGGTCGAT	129		ins Glu Val Asp		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0		0	11083630	755	0
740	2043c	196	PZA	pncA			Sreevatsan S AAC 1997			386	ins		AGGTCGATG	129		Ins Arg Ser Met		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	4/0		1	9056006	756	10
741	2043c	197	PZA	pncA			Hirano  K TLD 1997			390	SNP	T	G	130	130	Val/Gly	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0		1	9692180	757	20
742	2043c	198	PZA	pncA			Lee KW J Korean Med Sci 2001			389	ins		GG	130		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		1	11641519	758	0
743	2043c	199	PZA	pncA			Lemaitre N AAC 1999			389	ins		GG	130		Frameshift	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1988		France	Sequencing	Whole gene	ZHRES	500-1000		19/35	1/0		1	10390238	759	0
744	2043c	200	PZA	pncA			Scorpio A AAC 1997			389	del		G	130		Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	760	0
745	2043c	201	PZA	pncA			Lee KW J Korean Med Sci 2001			392	ins		G	131		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	761	0
746	2043c	202	PZA	pncA			Hirano  K TLD 1997			396	SNP	G	A	132	132	Gly/Asp	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	Z	>800	Proportion method	33/168	1/0		0	9692180	762	10
749	2043c	205	PZA	pncA			Sreevatsan S AAC 1997			395	ins		T	132		Frameshift		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		0	9056006	765	0
750	2043c	206	PZA	pncA			Marttila HJ AAC 1999			399	SNP	T	C	133	133	Ile/Thr	*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460	36/44	1/0	not tested	0	10390239	766	0
751	2043c	207	PZA	pncA			Morlock GP AAC 2000			399	SNP	T	A	133	133	Ile/Asn		1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0		0	11083630	767	0
752	2043c	208	PZA	pncA			Escalante P TuberLung Dis 1998			402	SNP	C	T	134	134	Ala/Val		1995-1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRP		Proportion method	40146	1/0	katG, 315, AGC/ACC; rpoB, 531, TCG/TTG;	1	10645449	768	10
754	2043c	210	PZA	pncA			Hou L Epi Infect 2000			401	ins		CC	134		Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRE	1000	Proportion method, BACTEC 460	35/65	1/0		0	10813147	770	0
755	2043c	211	PZA	pncA			Sreevatsan S AAC 1997			401	ins		C	134		Frameshift		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		0	9056006	771	0
759	2043c	215	PZA	pncA			Lee KW J Korean Med Sci 2001			404	del		G	135		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	775	0
760	2043c	216	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			408	SNP	A	G	136	136	Asp/Gly		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		0	16848344	776	0
761	2043c	217	PZA	pncA			Mestdagh M AAC 1999			407	ins		C	136		Frameshift	PZase negativity correlated to PZA-R, only 39 of 42 PZase positive test correl. to susceptibility	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460	23/62	1/0		0	10471589	777	0
762	2043c	218	PZA	pncA			Scorpio A AAC 1997			411	SNP	A	C	137	137	His/Pro	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	778	0
763	2043c	219	PZA	pncA			Sreevatsan S AAC 1997			411	SNP	A	G	137	137	His/Arg		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0		1	9056006	779	30
764	2043c	220	PZA	pncA			Cheng SJ AAC 2000			414	SNP	G	C	138	138	Cys/Ser				South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?		0	10681313	780	0
765	2043c	221	PZA	pncA			Scorpio A Nature Med 1996			414	SNP	G	A	138	138	Cys/Tyr			clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA (Colorado)	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	39910	1/0		1	8640557	781	10
766	2043c	222	PZA	pncA			Lee KW J Korean Med Sci 2001			413	ins		G	138		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	782	0
769	2043c	225	PZA	pncA			Morlock GP AAC 2000			417	SNP	T	G	139	139	Val/Gly		1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0		0	11083630	785	20
770	2043c	226	PZA	pncA			Sreevatsan S AAC 1997			417	SNP	T	C	139	139	Val/Ala		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0		1	9056006	786	10
771	2043c	227	PZA	pncA			Scorpio A AAC 1997			416	del		TG	139		Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	787	0
774	2043c	230	PZA	pncA			Cheng SJ AAC 2000			419	ins		G	140		Frameshift				USA	Sequencing	Whole gene	ZR	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	790	0
775	2043c	231	PZA	pncA			Cheng SJ AAC 2000			419	ins		GG	140		Frameshift				USA	Sequencing	Whole gene	ZHRSO	>900	Proportion method, BACTEC 460	59/59	1/0		0	10681313	791	0
777	2043c	233	PZA	pncA			Scorpio A Nature Med 1996			423	SNP	A	C	141	141	Gln/Pro			clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	invitro	1/0		1	8640557	793	20
780	2043c	236	PZA	pncA			Scorpio A AAC 1997			426	SNP	C	A	142	142	Thr/Lys	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		1	9055989	796	10
781	2043c	237	PZA	pncA			Scorpio A AAC 1997			426	SNP	C	T	142	142	Thr/Met	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	797	0
782	2043c	238	PZA	pncA			Cheng SJ AAC 2000			428	ins		GG	143		Frameshift				South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0?		0	10681313	798	0
784	2043c	240	PZA	pncA			Lemaitre N AAC 1999			434	del		G	145		Frameshift	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1987		France	Sequencing	Whole gene	ZHRE	1000-1500		19/35	1/0		0	10390238	800	0
785	2043c	241	PZA	pncA			Hirano  K TLD 1997			438	SNP	C	T	146	146	Ala/Val	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	India	Sequencing	Whole gene	ZRS	>800	Proportion method	33/168	1/0		0	9692180	801	10
786	2043c	242	PZA	pncA			Peridgao J MDR 2008			440	ins		CG	147		Frameshift		2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0		0	18573039	802	0
788	2043c	244	PZA	pncA			Brown TJ JMedMicro 2000			443	SNP	C	A	148	148	Arg/Ser	all sensitive isolates were WT and mutants and resistant ones had mutant genotypes	2000	4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460	13/18	1/0	C2431G(rpoB)	0	10882091	804	0
789	2043c	245	PZA	pncA			Scorpio A AAC 1997			443	del		G	148		Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	805	0
792	2043c	248	PZA	pncA			Lee KW J Korean Med Sci 2001			452	del		T	151		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	808	0
793	2043c	249	PZA	pncA			Morlock GP AAC 2000			459	SNP	C	A	153	153	Thr/Asn		1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0		0	11083630	809	0
795	2043c	251	PZA	pncA			Lemaitre N AAC 1999			465	SNP	T	G	155	155	Val/Gly	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1987		France	Sequencing	Whole gene	ZHRE	1500		19/35	1/0		1	10390238	811	20
796	2043c	252	PZA	pncA			Escalante P TuberLung Dis 1998			465	SNP	T	C	155	155	Val/Ala		1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRES		Proportion method	40146	1/0	katG, 315, AGC/ACC; rpoB, 531, TCG/TTG;	0	10645449	812	10
797	2043c	253	PZA	pncA			Lee KW J Korean Med Sci 2001			464	ins		T	155		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0		0	11641519	813	0
798	2043c	254	PZA	pncA			Scorpio A AAC 1997			473	del		C	158		Frameshift	some degree of mutational clustering in regions: 5-12, 69-85, 132-142	1992-1995	38 clinical isolates; 8 mutants made in vivo		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		0	9055989	814	0
799	2043c	255	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			477	SNP	T	C	159	159	Leu/Pro		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		1	16848344	815	30
800	2043c	256	PZA	pncA			Lee KW J Korean Med Sci 2001			477	SNP	T	G	159	159	Leu/Arg	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	816	20
802	2043c	258	PZA	pncA			Lee KW J Korean Med Sci 2001			479	ins		TGAC	160		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	818	0
804	2043c	260	PZA	pncA			Chan RCY JAC 2007			486	SNP	G	A	162	162	Gly/Asp	36% resistant to PZA, 80% of PZA-r had mutations, 80% mutants had resistance, 11% drug susceptible had mutations	1994-2004	250 drug-res. Mtb from Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZOREth	100mg/L	BACTEC MGIT 960	89/250	1/0	Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB)	1	17360809	820	10
805	2043c	261	PZA	pncA			Hou L Epi Infect 2000			500	ins		CG	167		Frameshift		1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZSHE	900	Proportion method, BACTEC 460	35/65	1/0		0	10813147	821	0
806	2043c	262	PZA	pncA			Cheng SJ AAC 2000			504	SNP	C	A	168	168	Thr/Asn				Canada	Sequencing	Whole gene	ZRO	300	Proportion method, BACTEC 460	59/59	1/0		0	10681313	822	0
809	2043c	265	PZA	pncA			Mestdagh M AAC 1999			513	SNP	C	T	171	171	Ala/Val	PZase negativity correlated to PZA-R, only 39 of 42 PZase positive test correl. to susceptibility	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460	23/62	1/0		0	10471589	825	10
810	2043c	266	PZA	pncA			Rodrigues V de F AAC 2005			513	SNP	C	A	171	171	Ala/Glu		1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40		1	15616332	826	10
811	2043c	267	PZA	pncA			Mestdagh M AAC 1999			512	del		C	171		Frameshift	PZase negativity correlated to PZA-R, only 39 of 42 PZase positive test correl. to susceptibility	1999	54 MDR mtb clinical strains	Rwanda	Sequencing	Whole gene	Z		BACTEC 460	23/62	1/0		0	10471589	827	0
812	2043c	268	PZA	pncA			Hirano  K TLD 1997			516	SNP	T	C	172	172	Leu/Pro	32/33 PZase negative mtb strains had mutations in pncA gene.	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0		1	9692180	828	30
816	2043c	272	PZA	pncA			Lee KW J Korean Med Sci 2001			530	ins		C	177		Frameshift	all PZA res strain concomitantly res. to ISN, RIF, ETH	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		0	11641519	832	0
819	2043c	275	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			543	SNP	G	T	181	181	Glu/Asp		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		0	16848344	835	0
820	2043c	276	PZA	pncA			Lemaitre N AAC 1999			546	SNP	T	C	182	182	Leu/Ser	16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml)	1997		France	Sequencing	Whole gene	ZHRS	500-2000ug/ml		19/35	1/0		0	10390238	836	0
821	2043c	277	PZA	pncA			Louw GE Int J Tuberc Lung Dis 2006			555	SNP	G	C	185	185	Ser/Thr		2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		1	16848344	837	10
822	2043c	278	PZA	pncA			Chan RCY JAC 2007			555	SNP	G	T	185	185	Ser/Ile		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		0	17360809	838	0
824	3793	2	EMB	embC			Srivastava S JMM 2009			731	SNP	GCG	ACC	244	244	Ala/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	embB E368A, S380R, P397Q, R460C; embC G288W, V303G; embR L172R	0	19010731	840	0
825	3793	3	EMB	embC			Srivastava S JMM 2009			741	SNP	C	C	247	247	Ala/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	8ug/ml	Proportion method, E-Test	44/44	1/0	embB A356F, A357V, L359I, E378A, A379D, Y384N, A388G, N399D; embC T270I, I297T	0	19010731	841	0
826	3793	4	EMB	embC			Srivastava S CurrMicro 2006			753	SNP	G	T	251	251	Leu/Arg	Study aimed at detecting embB and embC mutations in EMB-R M.tb.  Out of 23 EMB-R isolates tested, 16 (70%) carried mutations in the embB gene, with codon 306 being mutated most often (7 isolates = 20%). Ten isolates were also mutated in embC, with 8 (35%	Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	12ug/ml	Proportion method, E-Test	23/23	1/0	Ala254Gly and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.	0	16972132	842	0
827	3793	5	EMB	embC			Srivastava S CurrMicro 2006			762	SNP	C	G	254	254	Ala/Gly	Has associated mutations in embC and embB.	Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	12ug/ml	Proportion method, E-Test	23/23	1/0	Leu251Arg and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.	0	16972132	843	0
828	3793	6	EMB	embC			Sreevatsan S AAC 1997			810	SNP	C	T	270	270	Thr/Ile	Role unclear; also had a mutation at embB codon 306.	Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	16/19	1/0	Met306Val in embB.	0	9257740	844	0
829	3793	7	EMB	embC			Srivastava S JMM 2009			810	SNP	C	T	270	270	Thr/Ile		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	embB G406A	0	19010731	845	0
830	3793	8	EMB	embC			Srivastava S JMM 2009			816	SNP	G	A	272	272	Gly/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M, A431T; embC H285Y, M300R, A307T; embR A176V, I369T	0	19010731	846	0
832	3793	10	EMB	embC			Srivastava S JMM 2009			861	SNP	T	T	287	287	Val/Phe		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC Y309N; embR L320V, S326N, V350G, H351Q, R356G, I369T	0	19010731	848	0
833	3793	11	EMB	embC			Srivastava S JMM 2009			863	SNP	GGC	TGG	288	288	Gly/Trp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	embB E368A, S380R, P397Q, R460C; embC A244T, V303G; embR L172R	0	19010731	849	0
834	3793	12	EMB	embC			Srivastava S JMM 2009			864	SNP	GC	TG	288	288	Gly/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, A356F, L359I, R367P; embC M310K, Y327N	0	19010731	850	0
836	3793	14	EMB	embC			Srivastava S JMM 2009			888	SNP	A	G	296	296	Tyr/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embC R302G	0	19010731	852	0
837	3793	15	EMB	embC			Srivastava S JMM 2009			891	SNP	T	T	297	297	Ile/Leu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	E	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, S380D, P397T, G406D, G448V; embC W326R	0	19010731	853	0
838	3793	16	EMB	embC			Srivastava S JMM 2009			890	SNP	ATT	CTG	297	297	Ile/Leu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	48ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M; embC A247P, W326R; embR V7G	0	19010731	854	0
839	3793	17	EMB	embC			Srivastava S JMM 2009			891	SNP	T	C	297	297	Ile/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB S347I, E368D, R460L; embR R230W, I396T	0	19010731	855	0
840	3793	18	EMB	embC			Srivastava S JMM 2009			899	SNP	ATG	CGT	300	300	Met/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M, A431T; embC G272S, H285Y, A307T; embR A176V, I369T	0	19010731	856	0
841	3793	19	EMB	embC			Srivastava S JMM 2009			906	SNP	G	G	302	302	Arg/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embC Y296S	0	19010731	857	0
842	3793	20	EMB	embC			Srivastava S JMM 2009			909	SNP	G	C	303	303	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	embB E368A, S380R, P397Q, R460C; embC A244T, G288W; embR L172R	0	19010731	858	0
843	3793	21	EMB	embC			Srivastava S JMM 2009			920	SNP	GCG	ACC	307	307	Ala/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M, A431T; embC G272S, H285Y, M300R; embR A176V, I369T	0	19010731	859	0
844	3793	22	EMB	embC			Srivastava S JMM 2009			924	SNP	GC	AT	308	308	Gly/Asp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306I; embC T270I, Y296H', G325S	0	19010731	860	0
845	3793	23	EMB	embC			Srivastava S JMM 2009			927	SNP	A	A	309	309	Tyr/Asn		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EH	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A357S, A379T; embC V287F; embR L320V, S326N, V350G, H351Q, R356G, I369T	0	19010731	861	0
846	3793	24	EMB	embC			Srivastava S JMM 2009			930	SNP	G	A	310	310	Met/Lys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, A356F, L359I, R367P; embC G288V, Y327N	0	19010731	862	0
848	3793	26	EMB	embC			Srivastava S JMM 2009			977	SNP	TGG	CGT	326	326	Trp/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	E	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, E368Q, S380D, P397T, G406D, G448V; embC I297L	0	19010731	864	0
849	3793	27	EMB	embC			Srivastava S JMM 2009			981	SNP	A	A	327	327	Tyr/Asn		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, A356F, L359I, R367P; embC G288V, M310K	0	19010731	865	0
851	3793	29	EMB	embC			Ramaswamy SV AAC 2000			2214	SNP	G	A	738	738	Arg/Gln	Role unclear; see multiple other mutations.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	75/108	1/0	-16 C/T in embA;  Met306Ile in embB, Pro54Ser in RV3124.	0	10639358	867	0
853	3794	1	EMB	embA			Ramaswamy SV AAC 2000			-43	del		CG	-43	-43	Frameshift	Role unclear; see other mutations.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	20-30ug/ml	BACTEC 460	75/108	2/0	Met306Ile in embB at MIC=20ug/ml; Gly406Ser in embB at MIC=30ug/ml.	0	10639358	869	0
854	3794	2	EMB	embA			Ramaswamy SV AAC 2000			-49	SNP	C	T	-16	-16		Multiple mutations possible. Located in the embC-embA intergenic region, immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region, following a residue-replacing mutation in embB.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-40ug/ml	BACTEC 460	75/108	2/0	Arg738Gln in embC, Met306Ile in embB, and Pro54Ser in Rv3124 at MIC=40ug/ml; Ser501Trp at MIC>10ug/mL.	0	10639358	870	0
855	3794	3	EMB	embA			Ramaswamy SV AAC 2000			-37	SNP	C	T	-12	-12		Located in the embC-embA intergenic region, immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region, following a residue-replacing mutation in embB.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460	75/108	2/0	Gln497Lys in embB in one isolate; Gln497Lys in embB and Ser501Trp in iniA in another isolate.	0	10639358	871	0
856	3794	4	EMB	embA			Ramaswamy SV AAC 2000			-34	SNP	C	A	-11	-11		Located in the embC-embA intergenic region, immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region, following a residue-replacing mutation in embB.	Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	20ug/ml	BACTEC 460	75/108	1/0	Met306Ile in embB.	0	10639358	872	0
860	3794	8	EMB	embA			Ramaswamy SV AAC 2000			1050	SNP	G	A	350	350	Gly/Asp		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	2/0		0	10639358	876	0
861	3794	9	EMB	embA			Ramaswamy SV AAC 2000			1386	SNP	C	T	462	462	Ala/Val		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	1/0		0	10639358	877	0
862	3794	10	EMB	embA			Ramaswamy SV AAC 2000			2499	SNP	A	G	833	833	Asp/Ala		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	1/0		0	10639358	878	0
864	3795	1	EMB	embB			Srivastava S CurrMicro 2006			384	SNP	C	G	128	128	Val/Gly	Study aimed at detecting embB and embC mutations in EMB-R M.tb.  Out of 23 EMB-R isolates tested, 16 (70%) carried mutations in the embB gene, with codon 306 being mutated most often (7 isolates = 20%). Ten isolates were also mutated in embC, with 8 (35%	Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	5ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	880	0
865	3795	2	EMB	embB			Jain A IndJMedRes 2008			663	SNP	G	C	221	221	Ala/Gly		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	881	0
866	3795	3	EMB	embB			Jain A IndJMedRes 2008			674	SNP	GCG	AGC	225	225	Ala/Ser		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	882	0
867	3795	4	EMB	embB			Jain A IndJMedRes 2008			681	SNP	G	C	227	227	Val/Gly		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	883	0
868	3795	5	EMB	embB			Srivastava S CurrMicro 2006			717	SNP	T	C	239	239	Leu/Pro		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	256ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	884	0
870	3795	7	EMB	embB			Srivastava S JMM 2009			770	SNP	CGT	TGG	257	257	Arg/Trp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embC V287F, Y309N; embR A176V, R230W, I369T	0	19010731	886	0
871	3795	8	EMB	embB			Jain A IndJMedRes 2008			813	SNP	C	T	271	271	Ala/Val		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	887	0
873	3795	10	EMB	embB			Jain A IndJMedRes 2008			816	SNP	C	T	272	272	Ser/Ile		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	889	0
874	3795	11	EMB	embB			Wu  X  Chinese J of Antibiotics 2002			822	SNP	G	C	274	274	Arg/Pro													0	12622890	890	0
876	3795	13	EMB	embB			Jain A IndJMedRes 2008			842	SNP	TTT	CTG	281	281	Phe/Leu		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	892	0
877	3795	14	EMB	embB			Srivastava S JMM 2009			846	SNP	T	G	282	282	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	12ug/ml	Proportion method, E-Test	44/44	1/0	None in region embB, embC or embR'	0	19010731	893	0
879	3795	16	EMB	embB			Sreevatsan S AAC 1997			856	SNP	C	A	285	285	Phe/Leu		Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	69/99	1/0		0	9257740	895	0
880	3795	17	EMB	embB			Jain A IndJMedRes 2008			861	SNP	TT	GC	287	287	Phe/Cys		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	896	0
881	3795	18	EMB	embB			Jain A IndJMedRes 2008			860	SNP	TTT	GTG	287	287	Phe/Val		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	897	0
882	3795	19	EMB	embB			Jain A IndJMedRes 2008			879	SNP	T	C	293	293	Ile/Asn		2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16972132	898	0
884	3795	21	EMB	embB			Srivastava S JMM 2009			889	SNP	T	A	296	296	Asn/Lys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	embB E368D, G406S; embC I297T	0	19010731	900	0
886	3795	23	EMB	embB			Plinke C AAC 2006			891	SNP	C	T	297	297	Ser/Leu		2001	EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.	Germany	Sequencing	ERDR	E + INH + RIF	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16641474	902	0
887	3795	24	EMB	embB			Srivastava S CurrMicro 2006			897	SNP	C	A	299	299	Asp/Glu		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	2-6ug/ml	Proportion method, E-Test	23/23	4/0	Out of 4 isolates, 2 were WT in all other loci analyzed except for a synonymous mutation (GCA/GCC) at embB259. These isolates had MIC=4-6ug/ml. Both other isolates contained the embB mutation Glu378Ala (GAA/GCG); one of them was also mutated at embB Pro44	0	16972132	903	0
891	3795	28	EMB	embB			Sreevatsan S AAC 1997			918	SNP	G	A	306	306	Met/Ile		Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	11/0		1	9257740	907	13
892	3795	29	EMB	embB			Sreevatsan S AAC 1997			918	SNP	G	T	306	306	Met/Ile		Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	2/0		1	9257740	908	13
893	3795	30	EMB	embB			Sreevatsan S AAC 1997			918	SNP	G	C	306	306	Met/Ile		Published 1997	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	3/0		1	9257740	909	13
894	3795	31	EMB	embB			Lee HY YonseiMedJ 2002			918	SNP	T	C	306	306	Met/Thr		Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	2ug/ml	Proportion method	21/26	1/0	None in region amplified (see Gene coverage).	0	11854934	910	0
895	3795	32	EMB	embB			Srivastava S JMM 2009			927	SNP	G	C	309	309	Val/Gly		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, A310R, D311R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R	0	19010731	911	0
896	3795	33	EMB	embB			Srivastava S JMM 2009			930	SNP	C	G	310	310	Ala/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, D311R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R	0	19010731	912	0
897	3795	34	EMB	embB			Srivastava S JMM 2009			932	SNP	GAC	CGT	311	311	Asp/Arg	Reported as GAT/CGT but it should be GAC/CGT	Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, A310R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R	0	19010731	913	0
899	3795	36	EMB	embB			Srivastava S JMM 2009			936	SNP	A	G	312	312	His/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB S317T, A356F, L359I, R367P; embC G288V, M310K, Y327N	0	19010731	915	0
900	3795	37	EMB	embB			Lee HY YonseiMedJ 2002			942	SNP	GC	CG	314	314	Gly/Ala	A double substitution mutation with codon 322.	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	4ug/ml	Proportion method	21/26	1/0	Tyr322Cys on embB.	0	11854934	916	0
901	3795	38	EMB	embB			Tracevska T ResMicro 2004			942	SNP	GC	AG	314	314	Gly/Glu		Published 2004; isolates collected in 2001-2002	Patients with primary and relapsed pulmonary MDR-TB: 33 EMB-R and 33 EMB-S (N=66).	Latvia	Sequencing	ERDR	EHRS	N.S.	BACTEC radiorespiratory method (7.5ug/ml EMB), and absolute concentration method on L-J medium (cutoff 2.0ug/ml EMB)	33/66	1/0	None in region amplified (see Gene coverage).	0	15567277	917	0
902	3795	39	EMB	embB			Srivastava S JMM 2009			944	SNP	TAT	CTG	315	315	Tyr/Leu		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, N318S, V377G, E378A, Y384N, N400K, V452L	0	19010731	918	0
903	3795	40	EMB	embB			Srivastava S JMM 2009			951	SNP	G	C	317	317	Ser/Thr		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, A356F, L359I, R367P; embC G288V, M310K, Y327N	0	19010731	919	0
904	3795	41	EMB	embB			Srivastava S JMM 2009			953	SNP	AAC	CAT	318	318	Asn/His		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	embC T270I	0	19010731	920	0
905	3795	42	EMB	embB			Srivastava S JMM 2009			954	SNP	A	G	318	318	Asn/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, V377G, E378A, Y384N, N400K, V452L	0	19010731	921	0
906	3795	43	EMB	embB			Srivastava S JMM 2009			955	SNP	C	A	318	318	Asn/Lys		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, N368A, S380R, P397Q, G459A, R460C; embR T32P, D53H	0	19010731	922	0
909	3795	46	EMB	embB			Sugawara I Jpn J Infect Dis 2005			957	SNP	A	G	319	319	Tyr/Cys													0	16377878	925	0
910	3795	47	EMB	embB			Plinke C AAC 2006			957	SNP	A	C	319	319	Tyr/Ser		2001	EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.	Germany	Sequencing	ERDR	EHR	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16641474	926	0
911	3795	48	EMB	embB			Lee HY YonseiMedJ 2002			966	SNP	A	G	322	322	Tyr/Cys	A double substitution mutation with codon 314.	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	4ug/ml	Proportion method	21/26	1/0	Ala314Gly on embB.	0	11854934	927	0
913	3795	50	EMB	embB			Ramaswamy SV AAC 2000			984	SNP	A	G	328	328	Asp/Gly		Published 2000	Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0		0	10639358	929	0
914	3795	51	EMB	embB			Plinke C AAC 2006			984	SNP	T	G	328	328	Asp/Val		2001	EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.	Germany	Sequencing	ERDR	EHR	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.	0	16641474	930	0
915	3795	52	EMB	embB			Escalante P TuberLung Dis 1998			983	del		A	328		Frameshift	Out of 29 strains tested, 19 were resistant to INH + RIF, and most of these were also resistant to one or two other first-line drugs; 3 resistant only to STR; 1 resistant only to INH; and 2 were pan-susceptible. One strain had a frame-shift mutation at co	Published 1998; isolates collected 1995-1996	Isolates from patients with pulmonary, suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29	Peru	Sequencing	ERDR	E	N.S.	Proportion method	40146	1/0	None in region amplified (see Gene coverage).	0	10645449	931	0
917	3795	54	EMB	embB			Srivastava S JMM 2009			992	SNP	GGC	CGT	331	331	Gly/Arg		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	ER	16ug/ml	Proportion method, E-Test	44/44	1/0	embB V360M, G374V, G401S; embC I297T; embR D223E	0	19010731	933	0
922	3795	59	EMB	embB			Escalante P TuberLung Dis 1998			1041	SNP	G	C	347	347	Ser/Thr	Out of 29 strains tested, 19 were resistant to INH + RIF, and most of these were also resistant to one or two other first-line drugs; 3 resistant only to STR; 1 resistant only to INH; and 2 were pan-susceptible.	Published 1998; isolates collected 1995-1996	Isolates from patients with pulmonary, suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29	Peru	Sequencing	ERDR	E	N.S.	Proportion method	40146	1/0	None in region amplified (see Gene coverage).	0	10645449	938	0
923	3795	60	EMB	embB			Srivastava S JMM 2009			1041	SNP	G	T	347	347	Ser/Ile	Reported as AGC/ATT but it should be AGT/ATT	Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB E368D, R460L; embC I297T; embR R230W, I396T	0	19010731	939	0
924	3795	61	EMB	embB			Srivastava S JMM 2009			1067	SNP	GCG	TTT	356	356	Ala/Phe		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, L359I, R367P; embC G288V, M310K, Y327N	0	19010731	940	0
925	3795	62	EMB	embB			Srivastava S JMM 2009			1067	SNP	GCG	AGC	356	356	Ala/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB D299E, P371R, E378K; embR R230W, L292M, L303E	0	19010731	941	0
926	3795	63	EMB	embB			Srivastava S JMM 2009			1068	SNP	C	T	356	356	Ala/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, S366P, W395R, A434G, V435G, V436G, T437A; embC T270I	0	19010731	942	0
927	3795	64	EMB	embB			Srivastava S JMM 2009			1070	SNP	GCG	AGC	357	357	Ala/Ser		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	embB A379T; embC V287F, Y309N; embR L320V S326N, V350G, H351Q, R356G, I369T	0	19010731	943	0
928	3795	65	EMB	embB			Srivastava S JMM 2009			1071	SNP	C	T	357	357	Ala/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embB A356F, L359I, E378A, A379D, Y384N, A388G, N399D, G406P; embC A247P, T270I, I297T	0	19010731	944	0
929	3795	66	EMB	embB			Srivastava S JMM 2009			1074	SNP	GC	TG	358	358	Gly/Val		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB E368Q, S380D, P397T, G406D, G448V; embC I287L, W326R	0	19010731	945	0
930	3795	67	EMB	embB			Srivastava S JMM 2009			1076	SNP	CTG	ATT	359	359	Leu/Ile		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, A356F, R367P; embC G288V, M310K, Y327N	0	19010731	946	0
932	3795	69	EMB	embB			Srivastava S JMM 2009			1097	SNP	AGC	CCG	366	366	Ser/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB M306L, A356V, W395R, A434G, V435G, V436G, T437A; embC T270I	0	19010731	948	0
933	3795	70	EMB	embB			Srivastava S JMM 2009			1101	SNP	T	G	367	367	Arg/Pro		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	embB H312R, S317T, A356F, L359I; embC G288V, M310K, Y327N	0	19010731	949	0
934	3795	71	EMB	embB			Srivastava S JMM 2009			1103	SNP	GAA	CAG	368	368	Glu/Gln		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	embB G358V, S380D, P397T, G406D, G448V; embC I287L, W326R	0	19010731	950	0
935	3795	72	EMB	embB			Srivastava S JMM 2009			1104	SNP	A	T	368	368	Glu/Asp		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	embB S347I, R460L; embC I297T; embR R230W, I396T	0	19010731	951	0
936	3795	73	EMB	embB			Srivastava S CurrMicro 2006			1104	SNP	A	G	368	368	Glu/Ala		Published 2006	Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23	India	Sequencing	ERDR	E, EHR, HR, EH	32ug/ml	Proportion method	23/23	1/0	Met306Val, Ser380Arg, and Pro397Gln on embB.	0	16972132	952	0
938	3795	75	EMB	embB			Srivastava S JMM 2009			1107	SNP	T	C	369	369	Val/Ala		Published 2009	44 isolates from unrelated adult patients with pulmonary TB.	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	embB M306V, V309G, A310R, D311R, P375A, F398Y, P461S; embC T270I; embR G240R	0	19010731	954	0
940	0667	2	RIF	rpoB			Taniguchi H FEMS Micro 1996			1143	SNP	C	T	381	381	Ala/Val		Published 1997	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	200 ug/ml	Proportion method, absolute concentration method	21/39	(1/0)		0	8870258	2	0
941	0667	3	RIF	rpoB			Cavusoglu C JCM 2002	O'Sullivan DM JAntiChemo 2005		1470	SNP	G	T	490	490	Gln/His	Objective: determine drug resistance profiles of study population and detect and identify mutations present in the gene. Results: The most frequent mutation was 531 Ser/Leu. Comparisons were made of the frequencies of some mutations in Turkey compared to other countries: 3 mutations (526 TAC, 526 GAC and 516 GTC) were much lower in freq in the Turkish isolates.Novel mutations: 1) 490 CAG/CAT was outside the 81 bp hot-spot region 2) 515 ATG/ATC 3) 533 CTG/CCG 4) insertion of CGG betw 514-515. No association was found between specific mutations and MDR patterns. Postulates: (i) mutants isolated more freq in clinical practice have higher mean relative fitness and the prevalence of each mutant type depends on its ability to survive. (ii) mutations w/in 526 and 516 have shown to lead to high level RIF resistance; therefore, mutations continue to arise in these codons, probably due to abaility of Mtb to adapt to drug exp.	Published 2002	41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41	Turkey	Line probe assay, Sequencing	RRDR	R, RE, RHE, RH, RHES, RHS	N.S.	Proportion method	41/41	(1/0)		0	12454132	3	0
942	0667	4	RIF	rpoB			Schilke K IntJTubLungDis 1999			1512	SNP	A	C	504	504	Glu/Ala	Of note:  Outside of hot-spot region; Both isolates carried a separate missense mutation at codon 531, independently conveying drug resistance; isolates were recovered 5 wks apart from 2 different patients attending the same hospital; DNA finterprint analysis suggested a clonal relationship for those strainscontrary to findings of Sreevatsan et al and cannot be resolved with these findings.	Published 1999	87 MDR strains from 12 hospitals in Southern African regions + 13 RIF-resistant strains of M. africanum + 3 RIF-resistant strains of M. tuberculosis from Sierra Leone and Uganda + 2 RIF-resistant strains of M. tuberculosis from Namibia. N=105	South Africa	Sequencing	RRDR	MDR	N.S.	Not specified	105/105	(2/0)	Double mutation with 531	0	10423225	4	0
943	0667	5	RIF	rpoB			Heym B Lancet 1994			1516	SNP	C	G	505	505	Phe /Leu	Objective: To use new methods in a retrospective study of drug-resistant isolates, and have correlated the molecular findings with available clinical and microbiological data. Results: 13 of 39 resistant to R; 11 of 13 MDR (H,R) - 2 strains resistant to R but not H were from patients w/ poor compliance with chemotherapy	1991-1992	39 drug-resistant isolates analyzed: 16 strains resistant to H, 1 control - fully susceptible, 15 strains from other French hospitals but where susceptibility testing was done at the Pitie-Salpetriere lab. Taken from survey from 1991-1992 of drug resistance among isolates received for testing at Pietie-Salpetriere Hospital. N=39	La Reunion	PCR-SSCP		RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present	0	7914261	5	0
944	0667	6	RIF	rpoB			Stavrum R PlosOne 2009			1516	SNP	C	A	505	505	Phe /Leu		Published 2009		India	Sequencing	Whole gene	RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present	0	19234602	6	0
945	0667	7	RIF	rpoB			Wang Q JProtRes 2007			1515	SNP	T	C	505	505	Phe/Ser		Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0		0	17970586	7	0
947	0667	9	RIF	rpoB			Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998		1521	SNP	G	A	507	507	Gly/Asp	DNA analysis of the 32 RIF-R strains showed 14 different kinds of mutations affecting 9 amino acids within a 75-bp region of the gene. The highest mutation frequencies were observed at His526 (37.8%) and Ser531 (24.4%). Another characteristic finding was	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	PCR-SSCP, Sequencing	RRDR	R	N.S.	Absolute concentration method.	32/58	1/0	Location of double mutants not specified.	0	9003625	9	0
948	0667	10	RIF	rpoB			Bahrmand AR JCM 2009			1521	SNP	GC	AT	507	507	Gly/Asp		2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB Q513STOP, H526Y, S531F	0	19721079	10	0
949	0667	11	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1520	del		GGC ACC	507	507-508	del Gly Thr													0	10645439	11	0
953	0667	15	RIF	rpoB			Mani C JCM 2001			1524	SNP	C	G	508	508	Thr/Ser	Three new mutations within RRDR found, and two new mutations outside the RRDR.	Published 2001	RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50	India	Sequencing	RRDR	R	>128ug/ml	Proportion method	44/50	1/0	None described in the region sequenced.	0	11474030	15	0
954	0667	16	RIF	rpoB			Matsiota-Bernard P JCM 1998			1523	SNP	ACC	GCT	508	508	Thr/Ser		1995-1996	RIF-R clinical isolates. N=17	Greece	Line probe assay, Sequencing	RRDR	RHSEth	N.S.	Proportion method	17/17	1/0	None described in the region sequenced.	0	9431913	16	0
955	0667	17	RIF	rpoB			Zenteno-Cuevas R MemInstOswaldCruz 2009			1526	SNP	AGC	CAG	509	509	Ser/Gln		2007		Mexico	Sequencing	RRDR	HRSEZ	N.S.	BACTEC 460	15/25	1/0	None	0	19547874	17	0
956	0667	18	RIF	rpoB			Williams D AAC 1994			1527	SNP	G	C	509	509	Ser/Thr	Objective: To further characterize mutation assoicated with the RIF-resistent phenotype in TB, M. leprae and other pathogenic mycobacteria using a newly developed rapid PCr0based, DNA sequencing protocol targeted to a 305 bp region of the gene. Of note: It is not known if the Gln-527 or Thr-509 substituted amino acid could confer RIF-resistance. Further study is needed.	Published 1994	110 RIF-resistant and 10 RIF-susceptible strains from different geographic regions across the world. N=120	Canada	Sequencing	RRDR	RHES	N.S.	Proportion method	108/120	(1/0)	Double mutation with 526 (Asp)	0	7840574	18	0
957	0667	19	RIF	rpoB			Sekiguchi J JCM 2007 Jan			1527	SNP	C	G	509	509	Ser/Arg	Objective: Describe a new PCR-based method for simultaneous detection of mutations in eight genes responsible for resistance to six drugs. Results: S450L and S509R were novel mutations. S450L was susceptible indicated that it is not associated with RIF resistance.	Published 2007	105 and 33 clinical isolates were obtained from patients with pulmonary tuberculosis in Japan and Poland, respectively. N=138	Japan	Sequencing	RRDR	R, MDR	N.S.	Proportion method, BACTEC	28/138	(0/1)		0	17108078	19	0
959	0667	21	RIF	rpoB			Sajduda A JCM 2004	Ramaswamy S Musser JM Tubercle lung Dis 1998		1530	SNP	G	C	510	510	Gln/His		2000	105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible, 4 INH-sensitive, 3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(2/0)	rpoB: double mutation with 516 GAC/TAC	0	15184414	21	0
960	0667	22	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1533	SNP	T	C	511	511	Leu/Pro	A total of 23 distinct mutations in rpoB were identified. Over 90% of RIF-R strains had sequence alterations within a 69-bp region of the gene rpoB; most of these were missense mutations. Of the 121 RIF-R strains, 3 were WT in rpoB. The analysis also iden	Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	4/0	One of the strains was also Asp441Glu; another was Asp441Tyr; the third was also Ser437Thr.	1	8027320	22	30
961	0667	23	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1533	SNP	T	G	511	511	Leu/Arg		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.	0	8027320	23	0
963	0667	25	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1536	SNP	G	C	512	512	Ser/Thr		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	Also mutated at Leu436Pro.	0	8027320	25	0
964	0667	26	RIF	rpoB			Sajduda A JCM 2004			1536	SNP	G	T	512	512	Ser/Ile	Objective: To determine the drug resistance profiles and detect mutations present in the rpoB and katG genes as well as in the regulatory region of the inhA gene. Results:  3 new double mutations; 2 new novel mutations in single codons. 2 RMP-resistant strains contained no mutations. None of the RMP-sensitive isolates had mutations. 46 strains clustered into 14 groups with identical IS6110 RFLP patterns but direct links could not be established. Freq of mutations at codon 516 was high in Poland; could be due to geographic variations or a sample bias.	2001	105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible, 4 INH-sensitive, 3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	rpoB: double mutation with 516 GAC/GGC	0	15184414	26	0
968	0667	30	RIF	rpoB			Bahrmand AR JCM 2009			1539	SNP	A	A	513	513	Gly/Asn		2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB S512T, H526F, S531L	0	19721079	30	0
969	0667	31	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1539	SNP	A	T	513	513	Gln/Leu		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.	1	8027320	31	15
972	0667	34	RIF	rpoB			Kim BJ JCM 1997			1539	SNP	A	C	513	513	Gln/Pro		Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	Sequencing	RRDR	R	N.S.	Absolute concentration method.	32/58	2/0	Location of double mutants not specified.	0	9003625	34	0
973	0667	35	RIF	rpoB			Valim A JCM 2000			1539	SNP	A	C	513	513	Gln/His										82/100	1/0		0	10921994	35	0
974	0667	36	RIF	rpoB			Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005		1539	SNP	A	G	513	513	Gln/Arg													0	15814606	36	0
975	0667	37	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1538	ins		TTC	513	513-514	ins Phe		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.	0	8027320	37	0
976	0667	38	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1538	ins		TTC ATG	513	513-514	ins Phe Met		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.	0	8027320	38	0
977	0667	39	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1538	del		CAA TTC	513	513-514	del Gln Phe													0	10645439	39	0
978	0667	40	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1538	del		AA TTC ATG G	513	513-516	Gln/His and del Phe Met													0	10645439	40	0
979	0667	41	RIF	rpoB			Valim A JCM 2000			1541	del		TTC	514	514	del Phe		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	RHSZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had deletions: 515 (ATG-Met), 516(GAC-Asp) and change in codon 513 CAA(Gln)/CAC(His)	0	10921994	41	0
980	0667	42	RIF	rpoB			Taniguchi H FEMS Micro 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998		1543	SNP	C	G	514	514	Phe/Leu	Objective: To determine whether strains had mutations in regions other than the cluster I region or in other genes than the rpoB gene. Also to describe the relationship between the level of resistance ot RIF and mutational sites of the gene. Of Note:  2 mutations at 516 and 514 conferred low level resistance. Two explanations are possible: either there is a difference of amino acid change at codon 516 or there is a difference of other mutational sites harvored by the same strain.	Published  1996	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	12.5 ug/ml	Proportion method, absolute concentration method	21/39	(1/0)		0	8870258	42	0
982	0667	44	RIF	rpoB			Cavusoglu C JCM 2002			1541	ins		CGG	514	514-515	ins Arg		Published 2002	41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41	Turkey	Line probe assay, Sequencing	RRDR	R, RE,  RHE, RH, RHES, RHS	N.S.	Proportion method	41/41	(1/0)		0	12454132	44	0
983	0667	45	RIF	rpoB			Lipin MY CMI 2007			1541	del		C AT	514	514-515	Phe/Leu and del Met	Mutations in the RRDR of the rpoB gene were identified in 200 (92%) of the MDR isolates - with the most frequent mutations being in codons 516, 526, and 531, which were together found in 194 (89%) of the isolates. The paper also breaks down the mutations	1998-2001	MDR-TB isolates from pulmonary TB patients. Most patients were male (92%); mean age 43yrs; none were co-infected with HIV. N=217	Russia	Sequencing	RRDR	RHS, RHSK, RHSE	N.S.	Absolute concentration method.	217/217	1/0	None described in the region sequenced.	0	17403134	45	0
984	0667	46	RIF	rpoB			Valim A JCM 2000			1541	del		TTC ATG GAC	514	514-516	del Phe Met Asp		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	RHSZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had change in codon 513 CAA(Gln)/CAC(His)	0	10921994	46	0
985	0667	47	RIF	rpoB			Hillemann D Int J Tuberc Lung Dis 2005			1544	ins		TTC	515	515	ins Phe		2004	92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152	Kazakhstan, Germany	real-time sequencing FRET	RRDR	MDR	N.S.	N.S.	92/152	(1/0)		0	16229229	47	0
986	0667	48	RIF	rpoB			Sajduda A JCM 2004			1545	SNP	G	T	515	515	Met/Ile		2003	105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible, 4 INH-sensitive, 3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(8/0)	rpoB: double mutation with 516 GAC/TAC	0	15184414	48	0
987	0667	49	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1545	SNP	G	A	515	515	Met/Ile													0	10645439	49	0
988	0667	50	RIF	rpoB			Valim A JCM 2000			1544	del		ATG GAC CAG AAC	515	515-518	del Met Asp Gln Asn		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)		0	10921994	50	0
991	0667	53	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1548	SNP	A	T	516	516	Asp/Val		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.	1	8027320	53	15
992	0667	54	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1548	SNP	C	G	516	516	Asp/Glu		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	Also mutated at Leu436Pro.	0	8027320	54	0
993	0667	55	RIF	rpoB			Hillemann D Int J Tuberc Lung Dis 2005	Ramaswamy S Musser JM Tubercle lung Dis 1998		1548	SNP	A	G	516	516	Asp/Gly		2004	92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152	Kazakhstan, Germany	real-time sequencing FRET	RRDR	MDR	N.S.	N.S.	92/152	(1/0)		0	16229229	55	0
994	0667	56	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1548	SNP	A	C	516	516	Asp/Ala													0	10645439	56	0
995	0667	57	RIF	rpoB			Sajduda A JCM 2004			1548	SNP	C	G	516	516	Asp/Val		2004	105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible, 4 INH-sensitive, 3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	None	0	15184414	57	0
998	0667	60	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1547	del		GAC CAG	516	516-517	del Asp Gln		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.	0	8027320	60	0
1000	0667	62	RIF	rpoB			Mani C JCM 2001			1550	del		GAC	517	517	del Gln		Published 2001	RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50	India	Sequencing	RRDR	R	>128ug/ml	Proportion method	44/50	1/0	None described in the region sequenced.	0	11474030	62	0
1001	0667	63	RIF	rpoB			Sajduda A JCM 2004			1551	SNP	A	T	517	517	Gln/Leu		2005	105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible, 4 INH-sensitive, 3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	None	0	15184414	63	15
1002	0667	64	RIF	rpoB			Hillemann D AAC 2005			1550	del		CAG AAC	517	517-518	del Gln Asn		2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(1/0)	katG 315 AGC-ACC/Ser-Thr	0	15728936	64	0
1003	0667	65	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1550	del		CAG AAC	517	517-518	del Gln Asn		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.	0	8027320	65	0
1004	0667	66	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1550	del		G AAC AA	517	517-519	Gln/His and del Asn Asn													0	10645439	66	0
1006	0667	68	RIF	rpoB			Siddiqi N AAC 2002			1554	SNP	A	C	518	518	Asn/Thr		1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	RHO, ROS,  RO, RH	N.S.	Proportion method	94/126	(6/0)	1) rpoB dual mutaton with L511L; katG and inhA NM; gyrA A90A, S95T 3) rpoB dual mutation with R528P; gyrA S95T; rpsL NM; 4) rpoB dual mutaton with L511V; gyrA S95T; 5) gyrA S95T; 6) gyrA NM; 7) rpoB dual mutation with D516V; katG and inhA R463L	0	11796356	68	0
1007	0667	69	RIF	rpoB			Hillemann D AAC 2005			1554	SNP	A	T	518	518	Asn/Ile		2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(1/0)	None	0	15728936	69	0
1010	0667	72	RIF	rpoB			Bahrmand AR JCM 2009			1558	SNP	C	G	519	519	Asn/Lys		2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	50 ug/ml	Proportion method	41/286	2/0	rpoB L511V, Q513E, H526R	0	19721079	72	0
1011	0667	73	RIF	rpoB			Heym B Lancet 1994			1556	del		AAC	519	519	del Asn		1991-1992	39 drug-resistant isolates analyzed: 16 strains resistant to H, 1 control - fully susceptible, 15 strains from other French hospitals but where susceptibility testing was done at the Pitie-Salpetriere lab. Taken from survey from 1991-1992 of drug resistance among isolates received for testing at Pietie-Salpetriere Hospital. N=39	Russia, Netherlands	PCR-SSCP		MDR	10-100ug/ml	Proportion method	13/39	(2/0)	1) katG mutation present; inhA no mutation present; 2) katG no mutation present	0	7914261	73	0
1013	0667	75	RIF	rpoB			Taniguchi H FEMS Micro 1996			1563	SNP	T	C	521	521	Leu/Pro		Published  1998	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	< 0.39 ug/ml	Proportion method, absolute concentration method	21/39	(0/1)		0	8870258	75	30
1014	0667	76	RIF	rpoB			Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005		1563	SNP	G	A	521	521	Leu/Leu													0	15814606	76	0
1015	0667	77	RIF	rpoB			Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		1566	SNP	C	T	522	522	Ser/Leu		Published  1998	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(1/0)		1	7759399	77	30
1017	0667	79	RIF	rpoB			Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005		1566	SNP	C	G	522	522	Ser/Trp													0	15814606	79	15
1020	0667	82	RIF	rpoB			Bahrmand AR JCM 2009			1569	SNP	G	C	523	523	Gly/Ala		2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	25/0	rpoB T508A or S531L or L511V, or H526R	0	19721079	82	0
1021	0667	83	RIF	rpoB			Valim A JCM 2000			1572	SNP	T	G	524	524	Leu/Trp		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	MDR	N.S.	Proportion method	82/100	(1/0)	Same isolate had changes in codons 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu); 527 del AAG(Lys)	0	10921994	83	0
1022	0667	84	RIF	rpoB			Zenteno-Cuevas R MemInstOswaldCruz 2009			1572	SNP	T	C	524	524	Leu/Ser		2007		Mexico	Sequencing	RRDR	HR	N.S.	BACTEC 460	15/25	1/0	rpoB S531L	0	19547874	84	0
1024	0667	86	RIF	rpoB			Pozzi G JCM 1999			1575	SNP	C	T	525	525	Thr/Ile		Published April 2001	MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ	8-128ug/ml	Proportion method	37/37	(1/0)	Triple mutation with GAC516TAC and GGG523TGG	0	10074552	86	0
1033	0667	95	RIF	rpoB			Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998		1578	SNP	A	G	526	526	His/Arg		Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	PCR-SSCP, Sequencing	RRDR	R	N.S.	Absolute concentration method.	32/58	1/0	Location of double mutants not specified.	1	9003625	95	15
1034	0667	96	RIF	rpoB			Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		1578	SNP	A	C	526	526	His/Pro		Published  2001	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(2/0)		0	7759399	96	0
1035	0667	97	RIF	rpoB			Valim A JCM 2000			1578	SNP	C	G	526	526	His/Leu		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 527 del AAG(Lys)	0	10921994	97	0
1036	0667	98	RIF	rpoB			Sheng J JApplMicro 2008			1578	SNP	C	T	526	526	His/Leu		2002-2003	56 isolates from patients with pulmonary TB in Zhejiang province	China	PCR-SSCP , Sequencing	RRDR	R	N.S.	Agar proportion method	49/56	1/0	None in rpoB	0	18422555	98	0
1037	0667	99	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1578	SNP	A	T	526	526	His/Leu		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.	1	8027320	99	15
1038	0667	100	RIF	rpoB			Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1578	SNP	C	A	526	526	His/Gln		Published 1994	Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	Also mutated at Ser456Cys.	0	8027320	100	0
1039	0667	101	RIF	rpoB			Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		1578	SNP	C	G	526	526	His/Gln		Published 2003	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	>8ug/ml	BACTEC 460	26/36	(2/0)	Double mutation with 498 Val/Ala	0	7759399	101	0
1040	0667	102	RIF	rpoB			Siddiqi N AAC 2002	O'Sullivan DM JAntiChemo 2005		1582	SNP	G	T	527	527	Lys/Asn		1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	HRH	40 ug/ml	Proportion method	94/126	(2/0)	1) katG or inhA R463L; 2) katG or inhA R463L, rpoB dual mutation with L521L	0	11796356	102	0
1041	0667	103	RIF	rpoB			Valim A JCM 2000			1580	del		AAG	527	527	del Lys		1996-1998	100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu)	0	10921994	103	0
1043	0667	105	RIF	rpoB			Siddiqi N AAC 2002			1584	SNP	G	A	528	528	Arg/His		1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	HR, ROS	64-128 ug/ml	Proportion method	94/126	(2/0)	1) rpoB dual mutation with H526Y; gyrA S95T; rpsL NM;  2) rpoB 1 dual mutation with with S531W; katG and inhA R463L, Inh (C/T)	0	11796356	105	0
1044	0667	106	RIF	rpoB			Siddiqi N AAC 2002	O'Sullivan DM JAntiChemo 2005		1584	SNP	G	C	528	528	Arg/Pro		1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	ROS, RHO, RHS, RH	40-64 ug/ml*	Proportion method	94/126	(4/0)	1) rpoB dual mutation with N518T; gyrA S95T; rpsL NM; 2) katG or inhA NA; gyrA S95T; 3) katG or inhA R463L; rpsL K121K;  4) katG or inhA R463L; rpoB dual mutation with H526Y	0	11796356	106	0
1045	0667	107	RIF	rpoB			Zenteno-Cuevas R MemInstOswaldCruz 2009			1584	SNP	C	T	528	528	Arg/Pro		2007		Mexico	Sequencing	RRDR	HRSEZ	N.S.	BACTEC 460	15/25	1/0	None	0	19547874	107	0
1046	0667	108	RIF	rpoB			Wang Q JProtRes 2007			1614	SNP	C	A	538	538	Leu/STOP		Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0		0	17970586	108	0
1048	0667	110	RIF	rpoB			Donabella V Am J Respir Cell Mol Biol 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998		1593	SNP	C	T	531	531	Ser/Leu		Published 1994		USA	Sequencing	RRDR	R	N.S.		(1/9)	(1/0)		1	7946393	110	30
1049	0667	111	RIF	rpoB			Bodmer T JAC 1995			1593	SNP	C	G	531	531	Ser/Trp		Published 2005	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(1/0)		1	7759399	111	15
1050	0667	112	RIF	rpoB			Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		1593	SNP	G	T	531	531	Ser/Tyr		Published 2006	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	>8ug/ml	BACTEC 460	26/36	(1/0)		0	7759399	112	0
1051	0667	113	RIF	rpoB			Hillemann D AAC 2005			1593	SNP	G	T	531	531	Ser/Phe		2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(2/0)	katG 315 AGC-ACC/Ser-Thr	0	15728936	113	0
1052	0667	114	RIF	rpoB			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		1593	SNP	G	T	531	531	Ser/Cys													0	10645439	114	0
1053	0667	115	RIF	rpoB			Moghazeh SL AAC 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998		1599	SNP	T	C	533	533	Leu/Pro		1992-1995	RIF-R clinical isolates from strain database. N=24	USA	Sequencing	N.S	R	>32ug/ml	Proportion method	24/24	1/0	None described in the region sequenced.	1	8913484	115	30
1054	0667	116	RIF	rpoB			Valim A JCM 2000			1599	SNP	G	T	533	533	Leu/Pro		1996-1998	100 isolates from different regions of Brazil: 20 samples (19 RIF-resistant; 1 RIF-susceptible) from Sao Paulo. N=100	Brazil	Sequencing	RRDR	RH, RHS	N.S.	Proportion method	82/100	(2/0)	Same isolate had double mutation: 526 CAC(His)/CTG(Leu)	0	10921994	116	0
1056	0667	118	RIF	rpoB			Prammananan T CMI 2008			1605	SNP	C	A	535	535	Pro/His		2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 526 CAC/AGC His/Ser	0	18294243	118	0
1057	0667	119	RIF	rpoB			Wang Q JProtRes 2007			1614	SNP	T	C	538	538	Leu/Pro		Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0		0	17970586	119	30
1058	0667	120	RIF	rpoB			Prammananan T CMI 2008			1623	SNP	A	G	541	541	Glu/Gly		2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 526 CAC/TAC His/Tyr	0	18294243	120	0
1059	0667	121	RIF	rpoB			Pozzi G JCM 1999			1623	SNP	G	T	541	541	Glu/Gly		Published 2002	MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ	32-128 ug/ml	Proportion method	37/37	(1/0)	Triple mutation with CAC526GAC and TCG553GCG	0	10074552	121	0
1063	0667	125	RIF	rpoB			Heep M JCM 2001			1683	SNP	T	C	561	561	Ile/Thr		1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	N.S.	N.S.	Proportion method	111/111	(1/0)	Double mutation with S456L	0	11136757	125	0
1064	0667	126	RIF	rpoB			Hauck Y JAC 2009			1686	SNP	A	G	562	562	Glu/Gly		Published 2009	126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Santé des Armées in a total of 18 countries. This mutation confer low level RIF resistance	Various	Sequencing	RRDR	R	<1 ug/ml	MGIT 960	122/122	1/0	rpoB P564L	0	19520715	126	0
1065	0667	127	RIF	rpoB			Hauck Y JAC 2009			1692	SNP	C	T	564	564	Pro/Leu		Published 2009	126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Santé des Armées in a total of 18 countries. This mutation confer low level RIF resistance	Various	Sequencing	RRDR	R	<1 ug/ml	MGIT 960	122/122	1/0	rpoB E562G	0	19520715	127	0
1068	0667	130	RIF	rpoB			Chan RCY JAC 2007			1722	SNP	C	T	574	574	Ser/Leu		1994-2004	250 resistant isolates (resistant to 5 anti-tiuberculosis drugs) - none had apparent clonal features + 50 susceptible controls + 2 reference strains: ATCC 27294 H37Rv and ATCC 25117 H37Rag. N=302 isolates	Hong Kong	PCR-SSCP, Sequencing	RRDR	RHEZ	>64 ug/ml	Absolute concentration method.	221/250	1	katG 311 Asp/Gly	0	17360809	130	30
1071	0667	133	RIF	rpoB			Heep M JCM 2001			2016	SNP	G	T	672	672	Glu/Asp		1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	RH, RHE, RHZ, RHEZ	N.S.	Proportion method, BACTEC 460	111/111	(7/0)	Double mutation with S456W	0	11136757	133	0
1074	1908c	1	INH	katG			Baker LV AAC 2005			-1	ins		C	-1		Frameshift		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	CCC-CCG substitution at nt 723, Pro-Pro	0	15793126	136	0
1076	1908c	3	INH	katG			Heym B MolMicro 1995	Hazbon MH AAC 2006	Ramaswamy S Musser JM Tubercle lung Dis 1998	3	SNP	T	C	1	1	Val/Ala		1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	Russia	PCR-SSCP, Sequencing	Whole gene	MDR	1	Proportion method	34/37	1/0		0	7746145	138	0
1078	1908c	5	INH	katG			Siddiqi N AAC 2002	Hazbon MH AAC 2006		29	del		C	10	10	TRUNC 26aa		1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	H,HRO,HR,HROS	10ug/ml R, 1ug/ml I, 2ug/ml O 2ug/ml S	Proportion method	74/126	6/0	R463L KatG, S95T gyrA, H526R rpo, H526Y rpo, D516V rpo, S531L rpo, D94A gyrA, K121K rpsL	0	11796356	140	0
1082	1908c	9	INH	katG			Cockerill FR JID 1995			51	SNP	G	A	17	17	Ser/Asn		1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	0.12-1ug/ml	Proportion method	40071		Gly19Asp, Gln224Glu, Ala243Ser, Ala550Asp	0	7798673	144	10
1083	1908c	10	INH	katG			Cockerill FR JID 1995			57	SNP	G	A	19	19	Gly/Asp		1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	0.12ug/ml	Proportion method	40071	0/1	Pro2Ser, Ser17Asn, Gln224Glu, Ala243Ser, Ala550Asp	0	7798673	145	10
1085	1908c	12	INH	katG			Siddiqi N AAC 2002			98	ins		A	33	33	Truncation		1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HR,HRS	10ug/ml R, 1ug/ml I	Proportion method	74/126	4/0	S531W rpo, H526L rpo, R463L KatG, D516G rpo, H526R rpo	0	11796356	147	0
1087	1908c	14	INH	katG			Siddiqi N AAC 2002			110	del		G	37	37	TRUNC 45aa		1995	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HRO,HR	10ug/ml R, 1ug/ml I 2ug/ml O	Proportion method	74/126	2/0	S531W rpo, S95T gyrA, L511L H526R rpo	0	11796356	149	0
1088	1908c	15	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		114	SNP	G	A	38	38	Trp/STOP													0	16870753	150	0
1089	1908c	16	INH	katG			Sekigushi J JCM 2007			144	SNP	T	A	48	48	Leu/Gln		2007	Japan & Poland	Japan	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0	-15C/T upstream of mabA	0	17596354	151	0
1090	1908c	17	INH	katG			Baker LV AAC 2005			149	del		A	50	50	Frameshift		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	ahpC-34A	0	15793126	152	0
1091	1908c	18	INH	katG			Pretorius GS AAC 1995			155	del		CCGTCGCTGACC	52	52-57	del Ala Val Ala Asp Pro		1995	South Africa Switzerland, USA	USA	PCR-SSCP, Sequencing	1-221, 202-338, 319-558, 541-741, 722-942, 923-1140, 1120-1342, 1323-1526, 1507-1718, 1699-1915, 1896-2115, 2096-2310	HR	1.0 ug/ml	Proportion method	39/69	1/0		0	8619582	153	0
1093	1908c	20	INH	katG			Siddiqi N AAC 2002			185	ins		C	62	62	Truncation		1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HRS,HO,HR	10ug/ml R, 1ug/ml I 2ug/ml O	Proportion method	74/126	3/0	S531W rpo, K121K rpsL, S95T gyrA,H526R rpo	0	11796356	155	0
1094	1908c	21	INH	katG			Rouse DA AAC 1995	Hazbon MH AAC 2006		189	SNP	C	A	63	63	Asp/Glu	Catalase-negative clinical isolate.	1995	Clinical isolates.	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	50ug/ml	Absolute concentration method.	26/26	1/0		0	8585728	156	0
1095	1908c	22	INH	katG			Marttila HJ AAC 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998		194	ins		CCCC	65	65	Frameshift		1989-1995	Finland	Finland	Sequencing	Whole gene	H	1ug/ml	Disk elution method	54/56	1/0		0	8878604	157	0
1098	1908c	25	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	213	SNP	T	A	71	71	Ile/Asn													0	10645439	160	0
1099	1908c	26	INH	katG			Chan RCY JAC 2007			216	SNP	A	G	72	72	Asp/Gly	Error? Codon 71 is Ile. Codons 72 and 74 are both Asp, nt code GAC (mutate to GGC for Asn).	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	161	0
1103	1908c	30	INH	katG			Chan RCY JAC 2007			222	SNP	A	G	74	74	Asp/Gly		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	165	0
1104	1908c	31	INH	katG			Chan RCY JAC 2007			252	SNP	G	A	84	84	Met/Ile		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	166	0
1106	1908c	33	INH	katG			Marttila HJ AAC 1998			264	SNP	A	G	88	88	Gln/Arg													0	9736581	168	0
1107	1908c	34	INH	katG			Cockerill FR JID 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		270	SNP	G	A	90	90	Trp/STOP	no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		>32; catalase 5 mm	Proportion method	40071	1/0	none	0	7798673	169	0
1109	1908c	36	INH	katG			Gagneux S PLOS Path 2006			282	SNP	A	G	94	94	Asp/Gly													0	16789833	171	0
1110	1908c	37	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	282	SNP	A	C	94	94	Asp/Ala													0	10645439	172	0
1112	1908c	39	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		297	SNP	G	A	99	99	Gly/Glu													0	10645439	174	0
1113	1908c	40	INH	katG			Rouse et al MM 1996	Hazbon MH AAC 2006		312	SNP	G	T	104	104	Arg/Leu	site directed mutagenesis to create mutants.	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb					>500	N.S.	n/a	100 fold reduction in peroxidase activity		0	8939440	175	0
1114	1908c	41	INH	katG			Gagneux S PLOS Path 2006			312	SNP	G	A	104	104	Arg/Gln													0	16789833	176	0
1115	1908c	42	INH	katG			Gagneux S PLOS Path 2006			318	SNP	C	T	106	106	Ala/Val													0	16789833	177	0
1117	1908c	44	INH	katG			Baker LV AAC 2005	Hazbon MH AAC 2006		321	SNP	G	A	107	107	Trp/STOP		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	ahpC-30T	0	15793126	179	0
1120	1908c	47	INH	katG			Rouse DA AAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998		324	SNP	C	G	108	108	His/Gln	site directed mutagenesis,	1995	Washington D.C, Bethesda, South Korea	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	50	Absolute concentration method	26/26	1/0		0	8585728	182	0
1121	1908c	48	INH	katG			Gagneux S PLOS Path 2006			327	SNP	C	T	109	109	Ala/Val													0	16789833	183	0
1122	1908c	49	INH	katG			Wei CJ AAC 2003	Ramaswamy S Musser JM Tubercle lung Dis 1998		330	SNP	C	T	110	110	Ala/Val	site directed mutagenesis,	2003					H						0	12543676	184	0
1124	1908c	51	INH	katG			Lavender C AAC 2005			351	SNP	A	C	117	117	Asp/Ala		2001-2003	Victorian Infectious Diseases Reference Laboratory	Australia	Sequencing	Whole gene	HR	0.4 ug/ml I	BACTEC	52/104	1/0		0	16189082	186	0
1128	1908c	55	INH	katG			Marttila HJ AAC 1998			363	SNP	G	T	121	121	Gly/Val		1993-1995	Clinical isolates	Russia	Sequencing.	Whole gene	HR	N/A	Proportion method	24/27	1/0	Asp516Val in rpoB	0	9736581	190	0
1131	1908c	58	INH	katG			Ramaswamy SV AAC 2003			371	ins		G	124	124	Frameshift			38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates	USA, Mexico	Sequencing			>256	BACTEC 460, E-test	38/121	1/0	G-9A (oxyR-ahpC)	0	12654653	193	0
1133	1908c	60	INH	katG			Heym B MolMicro 1995	Musser Clin Microb Rev 1995		374	ins		CAT	125	125	ins His	Error? Review paper says insertion was CAT, Ile - but CAT codes for His. Can't access primary paper (French).	1995	Isolates from Pitries hospital in France 1991-92	Yugoslavia	PCR-SSCP, Sequencing	Whole gene	H		Proportion method	34/37	1/0		0	7746145	195	0
1135	1908c	62	INH	katG			Chan RCY JAC 2007			381	SNP	A	C	127	127	Gln/Pro		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	197	0
1136	1908c	63	INH	katG			Fang Z JCM 1999	Hazbon MH AAC 2006		384	SNP	G	C	128	128	Arg/Pro		1990-1997	Scottish Mycobacterial refererence lab	United Kingdom	PCR-SSCP, Sequencing	2268-2288&2595-2615,  2781-2801&3115-3135, 3366-3386& 3633-3653, 3661-3681& 3973-3993	H,E,R,P,Rifa,Cip,Ami,S,Proth		BACTEC 460	10/715	1/0	Leu511Pro rpoB	0	10074516	198	0
1139	1908c	66	INH	katG			Hazbon MH AAC 2006		Ramaswamy S Musser JM Tubercle lung Dis 1998	414	SNP	A	G	138	138	Asn/Ser		2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing		H	0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	1/0		0	11158123	201	0
1140	1908c	67	INH	katG			Morlock GP AAC 2003			414	SNP	A	C	138	138	Asn/Thr		2003	USA,Russia, Brazil	USA, Russia, Brazil	Sequencing	Whole gene	H	>32ug/ml	Microplate alamar blue assay method	17/41	1/0		0	14638486	202	0
1143	1908c	70	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	420	SNP	G	A	140	140	Ser/Asn	Primary paper not found.	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing			0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	9/0		0	10645439	205	10
1145	1908c	72	INH	katG			Hai Hua Lin TubercRespirDis 2007			420	SNP	C	A	140	140	Ser/Arg		2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	katG N238K	0	2007582629	207	10
1146	1908c	73	INH	katG			Sekigushi J JCM 2007			424	SNP	G	C	141	141	Leu/Phe		2007	Japan & Poland	Japan, Poland	Sequencing	Whole gene			Proportionmethod, BACTEC MGIT 960	38/138	2/0		0	17596354	208	0
1147	1908c	74	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	426	SNP	A	C	142	142	Asp/Ala													0	10645439	209	0
1148	1908c	75	INH	katG			Gagneux S PLOS Path 2006			429	SNP	A	C	143	143	Lys/Thr													0	16789833	210	0
1150	1908c	77	INH	katG			Rouse et al MM 1996	Hazbon MH AAC 2006		444	SNP	T	G	148	148	Leu/Arg	site directed mutagenesis to create mutants.	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S.	n/a			0	8939440	212	0
1152	1908c	79	INH	katG			Marttila HJ AAC 1998			465	SNP	A	C	155	155	Tyr/Ser	Paper doesn't confirm nts but says it is a point mutation, and this is the only single point mutation that works.	1993-1995	Russia	Russia	Sequencing.	Whole gene	HRSK	1 ug/ml I, 5 ug/ml R	Proportionmethod	24/27	1/0	Arg463Leu katG,     Ser 531Leu rpoB	0	9736581	214	0
1153	1908c	80	INH	katG			Gagneux S PLOS Path 2006			465	SNP	A	G	155	155	Tyr/Cys		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	3	0	16789833	215	0
1154	1908c	81	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	480	SNP	C	T	160	160	Ser/Leu													0	10645439	216	0
1156	1908c	83	INH	katG			Cockerill FR JID 1995			507	SNP	G	C	169	169	Gly/Ala		1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	1ug/ml	Proportion method	40071	1/0	Pro2Ser, Ser17Asn, Met126Ile,  Gln224Glu, Ala264Val, Ala281Val, Try337Cys, Arg463Leu	0	7798673	218	0
1158	1908c	85	INH	katG			Chan RCY JAC 2007			516	SNP	C	T	172	172	Ala/Val		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	220	0
1159	1908c	86	INH	katG			Chan RCY JAC 2007			528	SNP	G	A	176	176	Met/Ile		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	3	0	17360809	221	0
1160	1908c	87	INH	katG			Secondary Publication: Hazbon MH AAC 2006	Hazbon MH AAC 2006		540	SNP	C	A	180	180	Thr/Lys													0	16870753	222	0
1162	1908c	89	INH	katG			Chan RCY JAC 2007			558	SNP	G	T	186	186	Gly/Val		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	224	0
1165	1908c	92	INH	katG			Chan RCY JAC 2007			572	del		G	191	191	Frameshift		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	227	0
1166	1908c	93	INH	katG			Morlock GP AAC 2003			584	SNP	G	A	195	195	Glu/Lys		2003	USA,Russia, Brazil	USA	Sequencing	Whole gene	Eth	1	Microplate alamar blue assay	17/41	0/1	nt 280 T/G inh ORF	0	14638486	228	0
1167	1908c	94	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	Hazbon MH AAC 2006	594	SNP	G	A	198	198	Trp/STOP													0	10645439	229	0
1170	1908c	97	INH	katG			Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998		650	ins		N	217	217	Frameshift?	Primary paper not found.												0	10645439	232	0
1171	1908c	98	INH	katG			Chan RCY JAC 2007			655	SNP	C	A	218	218	Asn/Lys		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	233	0
1174	1908c	101	INH	katG			Ghiladi RA J Am Chem Soc 2005			687	SNP	A	T	229	229	Tyr/Phe	LAB MUTATION												0	16173777	236	0
1175	1908c	102	INH	katG			Chan RCY JAC 2007			690	SNP	T	C	230	230	Val/Ala		1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong.	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1	0	17360809	237	0
1198	B000019	1	AMI	rrs			Maus CE AAC 2005 Aug			4202	SNP	A	G	1401		rRNA gene	Sequential mutant selection in vitro implicates rrs mutations as molecular basis of resistance to each of the four drugs tested: Kamycin, amikacin, capreomycin, and viomycin. Testing of 16 clinical isolates shows rrs and tlyA mutations responsible for r	Published 2005	M.tb laboratory strains used for in-vitro selection of mutants; clinical isolates obtained from CDC. N=16	USA	Sequencing	Whole gene	KAmiCap	K >80ug/ml, Ami >64ug/ml, CAP 20-80ug/ml	N.S.	16/16	11/0	9 isolates had no additional mutaitons; one had a mutation at rrs A514C; and one had a mutation at rrs A514C and T1239C.	0	16048924	1170	0
2203	0667	2	RIF	rpoB	0	CJ	Taniguchi H FEMS Micro 1996			1143	SNP	C	T	381	381	Ala/Val		Published 1997	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	200 ug/ml	Proportion method, absolute concentration method	21/39	(1/0)		0	8870258	2	0
